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ABSTRACT 
Opioid abuse is one of the most significant drug-related public health threats in the 
United States (U.S. Drug Enforcement Agency, 2016).  Approximately 115 Americans die every 
day from an opioid overdose in the United States (Center for Disease Control and Prevention, 
2017).  Coupled with counseling, medication assisted treatment (MAT) can successfully treat 
opioid use disorder and sustain recovery by providing a more individualized approach to therapy 
(Substance Abuse and Mental Health Services Administration, 2016). 
The purpose of this project was to assist a primary care clinic (PCC) in Fargo, ND with 
the development, implementation, and evaluation of a buprenorphine-naloxone MAT option for 
opioid use disorder (OUD) patients in collaboration with a chemical dependency residential 
center (CDRC).  This was accomplished through the development of evidence-based guidelines, 
consent for treatment forms, and a provider order-set, and educating nurses at the primary care 
clinic on the use of the Clinical Opiate Withdrawal Scale.  Additionally, nurse practitioner 
confidence in utilizing medication-assisted treatment was evaluated two months post-project 
implementation using a 5-point Likert Scale, while nurse practitioners also identified strengths 
and weaknesses of the project via free hand data entry.   
The analysis at the conclusion of this project included the overall results of the pre and 
posts implementation Likert Scale surveys and qualitative questionnaires.  Nurse Practitioner 
confidence in treating OUD patients, knowledge of community resources for addiction resources, 
understanding the pathophysiology of opioid addiction, and willingness to provide medication 
assisted treatment improved post-implementation.  Through analysis of the qualitative 
questionnaire, nurse practitioners indicated positive feelings about the program and the working 
relationship within the PCC and with the CDRC.  Lack of experience working with OUD 
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patients was indicated in nurse practitioner responses as a weakness.  Results generalized within 
the confines of the PCC may indicate more experience working with OUD patients could lead to 
increased nurse practitioner confidence in treating the patient population.    
 v 
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CHAPTER ONE. INTRODUCTION 
Background 
A report by the U.S. Drug Enforcement Agency referred to opioids (including 
prescription drugs, heroin, and fentanyl) as the most significant drug-related threats to the United 
States (US) (2016).  In 2017, an estimated 11.4 million people aged 12 years or older misused 
opioids in the past year (Bose, Hedden, Lipari, & Park-Lee, 2018).  According to the Center for 
Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS) (2017), the 
rate of drug overdose deaths involving natural and semisynthetic opioids (oxycodone and 
hydrocodone), heroin, and synthetic opioids other than methadone (fentanyl, fentanyl analogs, 
and tramadol) have all increased dramatically since 1999 (Hedegaard, Warner, & Miniño).  In 
fact, the number of opioid overdose deaths in 2016 was five times higher than in 1999, with 
approximately 115 Americans dying every day from an opioid overdose in the U.S. (CDC, 
2017).  Of the 42,000-total opioid-related deaths in 2016, a staggering 40% of the overdose 
fatalities involved a prescription opioid (CDC, 2017).  
According to U.S. State Prescribing Rates, in 2016, North Dakota (ND) had one of the 
lowest retail opioid prescriptions dispensing rates in the U.S. at 47.8 per 100 persons, while, in 
comparison, Alabama and Arkansas’ dispensing rate was 121.0 and 114.6 respectively per 100 
persons (CDC, 2017).  Although ND also had one of the fewest opioid related death rates in the 
country, the state was not immune to the increasing trend of opioid associated fatalities.  In 2016, 
54 opioid-related overdose deaths occurred in ND, which accounted for 70% of all drug-related 
overdose deaths.  This was an increase from 34 deaths the year prior and from the 11 opioid 
related deaths in 2013 (Kaiser Family Foundation, 2018). 
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Significance 
Providers faced the difficult task of treating pain while also addressing the abuse 
associated with years of narcotic over prescribing.  As prescription opioids sold to pharmacies, 
hospitals, and doctors’ offices nearly quadrupled from 1999 to 2010, the number of overdose 
related deaths from prescription painkillers also quadrupled (CDC, 2017).  Such factors created a 
public health epidemic, which required a multifaceted approach to treating addiction and 
preventing opioid related deaths. 
According to the Substance Abuse and Mental Health Services Administration 
(SAMSHA), medication assisted treatment (MAT) incorporates the use of medications to treat 
patients with substance abuse disorders.  Coupled with counseling, MAT can successfully treat 
opioid use disorder (OUD) as well as sustain recovery by providing a more individualized 
approach to therapy (SAMSHA, 2016).  “Treatment has shown to improve patient survival, 
increase retention in treatment, decrease illicit opiate use and other criminal activity among 
people with substance use disorders, increase patients’ ability to gain and maintain employment, 
and improve birth outcomes among women who have substance use disorders and are pregnant” 
(SAMSHA, 2015, para. 10).  
At the state and national levels, significant gaps between treatment need and capacity 
existed.  MAT had been underutilized despite evidence that MAT improves treatment retention, 
reduces opioid use, and reduces risk behaviors that could lead to comorbidities such as HIV and 
hepatitis (Jones, Campopiano, Baldwin, & McCance-Katz, 2015).  Slow adoption of evidence-
based treatment options for opioid dependence may have been attributed to misapprehensions 
regarding the substitution of one opioid for another.  Additionally, discrimination against MAT 
patients, lack of training for primary care providers, and negative opinions toward MAT in 
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communities and among health care professionals may all act as barriers to the adoption of MAT 
programs (SAMSHA, 2015). 
Offering MAT may improve adherence to addiction treatment.  Conversely, the efficacy 
of behavioral counseling in treating opioid dependent patients was not universally accepted.  
Some studies have failed to demonstrate improvement in completion or retention rates when 
combining MAT for opioid dependence with counseling services (Fiellin et al., 2013; Ling et al., 
2013; Weiss et al., 2011) while others have (Moore et al., 2016).  However, a lack of 
psychosocial support had been found to be a barrier for providers prescribing buprenorphine 
(Andrilla, Coulthard, & Larson, 2017; Hutchinson, et al., 2014).  To improve provider 
confidence in prescribing buprenorphine for treatment of OUD, a primary care clinic utilized the 
counseling services of a chemical dependency residential center. 
Problem Statement 
Opioid addiction is an epidemic affecting every state in the nation.  Although North 
Dakota’s overdose deaths have been lower than the national average, the statistics remain 
alarming (Kaiser Family Foundation, 2018).  Methadone had historically been used to treat 
opioid addiction in the U.S. but can only be prescribed in treatment programs certified by 
SAMHSA.  However, the availability of and access to treatment centers have not met the 
increasing need for MAT services created by the prescription drug dependence epidemic 
(Jenkins & Ravert, 2013).  Opportunities within the primary care setting exist to manage OUD, 
specifically with MAT, which have positive benefits across numerous values.  Such values 
included lowering mortality risk, transmission of HIV and hepatitis through sharing of needles, 
contracting STIs through unsafe sexual contact, and other risk-taking behaviors (SAMSHA, 
2015).  However, primary care MAT for OUD haven’t been utilized due to a variety of barriers 
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such as provider confidence in their ability to treat OUD patients, organizational support, and 
need for psychosocial counseling of patients (Hutchinson, et al., 2014). 
Project Description 
Project Purpose 
The project purpose was to assist a clinic in Fargo, ND with the development, 
implementation, and evaluation of a MAT option for patients with OUD.  The primary care 
clinic (PCC) nurse practitioners (NPs) began treating OUD patients using a MAT program.  The 
program also worked in partnership with a chemical dependency residential center (CDRC) in 
Fargo, ND, which provided addiction counseling.  Guidelines, consent for treatment forms, 
provider order-set and screening, examination, and other health related considerations were 
created to facilitate the transition to providing MAT.  Nurse practitioner confidence in treating 
the OUD patient population and NP’s opinions of the program’s effectiveness were evaluated 
after receiving a buprenorphine-naloxone (BUP/NX) prescription waiver and again two months 
after implementation of the project.  
Project Objectives 
The project objectives were as follows:  
1. Evidence-based guidelines, consent for treatment forms, and a provider order-set 
necessary for MAT program implementation are completed prior to program 
implementation.  The BUP/NX consent and agreement forms are in Appendix B, C, and 
D; provider order-set is in Appendix G. 
2. Prior to implementation, nurses at the PCC are knowledgeable about and successfully 
using Clinical Opiate Withdrawal scale (COWS).  An example of the COWS is in 
Appendix A.  
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3. PCC nurse practitioners will feel confident in treating OUD using BUP/NX MAT. 
4. At two months post-implementation, providers are able to identify program strengths and 
weaknesses.   
Chapter One briefly introduced the background and significance of opiate use in the 
United States and provided a brief description of the dissertation project and objectives.  The 
ensuing chapter will review the literature on the medication buprenorphine, providing BUP/NX 
MAT through primary care, and describe the theoretical framework for the project. 
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CHAPTER TWO. LITERATURE REVIEW AND THEORETICAL FRAMEWORK 
A literature review on opioid addiction treatment practices using buprenorphine in the 
primary care setting revealed several recent articles.  Multiple databases were searched, 
including Academic Search Premier (EBSCO), CINAHL, PubMed, and Medline.  Key words 
included buprenorphine, naloxone, primary care, barriers, medication assisted treatment, opioid, 
addiction, and outcomes.  Inclusion criteria included primary care, medication assisted treatment 
with buprenorphine or buprenorphine-naloxone, and opioid use disorder.  Articles that included 
other medication assisted treatment treatments such as methadone and naltrexone were also 
included but only when compared with buprenorphine or buprenorphine-naloxone.  Articles 
about treatments using buprenorphine or buprenorphine-naloxone and subjects who did not have 
opiate addiction were excluded. 
Literature Review 
The American Society of Addiction Medicine (ASAM) defined addiction as “a primary, 
chronic disease of brain reward, motivation, memory, and related circuitry.  Dysfunction in these 
circuits leads to characteristic biological, psychological, social, and spiritual manifestations.  
This is reflected in an individual pathologically pursuing reward and/or relief by substance use 
and other behaviors” (2011, para. 1).  The Diagnostic and Statistical Manual of Mental Disorders, 
5th edition (DSM-5) criteria for diagnosis of OUD described two or more symptoms must be 
experienced within a 12-month period to define OUD with severity being determined by the 
number of symptoms experienced (American Psychiatric Association, 2018).  Symptoms of 
OUD include:   
• Using larger amounts of opioids or over a longer period than intended. 
• There is a persistent desire or unsuccessful efforts to cut down or control opioid use. 
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• A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or 
recover from its effects. 
• Craving or a strong desire to use opioids. 
• Failure to fulfill major role obligations at work, school, or home due to recurrent opioid 
use. 
• Continued use despite recurrent or persistent social or interpersonal problems caused or 
exacerbated by opioid use.   
• Giving up or reducing social, occupational, or recreational activities due to opioid use.   
• Recurrent opioid use in physically hazardous situations.   
• Continued opioid use despite physical or psychological problems caused or exacerbated 
by its use. 
• Tolerance (marked increase in amount; marked decrease in effect). 
• Withdrawal syndrome as manifested by cessation of opioids or use of opioids (or a 
closely related substance) to relieve/avoid withdrawal symptoms. 
The Institute of Medicine’s (IOM) report The Future of Nursing: Leading Change, 
Advancing Health recommended removal of barriers in order to allow advanced practice 
registered nurses to practice to the full extent of their education in order to meet the needs of a 
changing health system (2011).  Furthermore, NPs offer an opportunity to address gaps in patient 
access to high quality, patient-centered, and affordable health care, particularly in rural areas.  A 
study by Ortiz et al. (2018) considered how select patient outcomes in rural health clinics 
differed between eight southern states that had restricted, reduced, or expanded scope of practice.  
The quality of patient outcomes was not reduced when Advanced Practice Registered Nurse 
(APRN) roles were expanded (Ortiz et al., 2018).  The expansion of APRN autonomy may help 
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to relieve burden of physicians in terms of providing diagnoses, prescriptions, treatments, 
consultations, and other services.   
Such consideration may be applicable to the NP providing MAT for OUD patients.  In 
fact, the U.S. Department of Health and Human Services (HHS) identified the current misuse, 
abuse, and mortality associated with opiate abuse as a national crisis and identified five priorities 
for which to focus their efforts.  Such priorities included better addiction prevention, treatment 
and recovery services, overdose reversing drugs, data collection, pain management, and research 
(2017).  To improve access, $485 million in grants was offered to each state for evidence-based 
prevention and treatment programs (HHS, 2017).  Such grants were distributed through 
SAMHSA and supplemented by additional grants provided to state and local communities (HHS, 
2017).  Grant funding, along with recent changes to prescriptive privileges for NPs and physician 
assistants (PAs), allowed an opportunity for additional MAT services.  
The Drug Addiction Treatment Act of 2000 (DATA 2000) enabled qualifying physicians 
to obtain a waiver to practice MAT for OUD in primary care practice with buprenorphine 
(SAMHSA, 2016).  However, until 2016, NPs and PAs were prohibited from prescribing and 
treating OUD with buprenorphine.  On July 22, 2016, the Comprehensive Addiction and 
Recovery Act (CARA) was signed into law.  Section 303 of the CARA expanded prescribing 
privileges to NPs and PAs for five years until October 1, 2021 (SAMHSA, 2018).  Nurse 
Practitioners and PAs may apply for a waiver to prescribe buprenorphine, a partial opioid agonist 
used to treat opioid addiction, following 24 hours of training.  Topics covered in the training 
sessions included opioid maintenance and detoxification; clinical use of FDA-approved drugs for 
MAT, patient assessment and treatment planning, psychosocial services, staff roles, and 
diversion control (American Society of Addiction Medicine, 2018).  Once a waiver had been 
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received, the NP or PA may prescribe buprenorphine for up to 30 patients immediately.  After 
one year or practice, a provider may apply for a waiver to allow for treatment of up to 100 
patients (American Society of Addiction Medicine, 2018).  
Despite the adoption of DATA 2000 and expansion to allow APRNs and PAs to prescribe 
buprenorphine, primary care opioid addiction therapy has been severely underutilized.  Too few 
providers have a waiver to prescribe the medications that would allow patients with OUD to 
receive MAT.  A greater number of primary care providers, outside of addiction specialists, are 
needed to provide MAT treatment for OUD (Jenkin & Ravert, 2013).   
A treatment program contributes to the health of the Fargo community by decreasing the 
risk of contracting diseases such as HIV, hepatitis, and STIs though intravenous drug use and 
poor choices.  According to the SAMHSA (2017), “people with substance use disorders are at 
greater risk of contracting or transmitting an HIV infection because the misuse of drugs and/or 
alcohol can impair judgment and contribute to poor decision making” (para. 2).  
Sharing needles, drug paraphernalia, or unprotected sex with infected individuals 
increases the likelihood of contracting diseases like HIV and hepatitis B and C.  One study by 
Zibbell et al. (2018) found the annual incidence rate of acute hepatitis C infection increased more 
than 2-fold (from 0.3 to 0.7 cases/100,000) from 2004 to 2014 with a significant correlation to 
the use of opioid injection.  Efforts to increase the number of MAT programs may prevent the 
spread of HIV, hepatitis, and other transmittable infections by improving treatment retention 
rates and decreasing risk-taking behaviors (SAMHSA, 2015). 
What is Buprenorphine? 
According to SAMHSA (2016), “unlike methadone treatment, which must be performed 
in a highly structured clinic, buprenorphine was the first medication to treat opioid dependency 
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that was permitted to be prescribed or dispensed in physician offices, significantly increasing 
treatment access” (para. 3).  The reason may be due to the unique properties of the medication 
itself.  Buprenorphine is a partial opioid agonist, which means that there is less risk of euphoria, 
physical dependence, and potential for abuse or misuse.  Buprenorphine has a “ceiling effect” 
which means that the agonist effects of the medication increases linearly with higher doses until 
reaching a plateau.  Once reached, no further doses of buprenorphine will increase the agonist 
effect, thus lowering the risk of abuse or side effects compared to full opioid agonists (heroin or 
oxycodone) or methadone (The National Alliance of Advocates for Buprenorphine Treatment 
(NAABT), n.d.).  
Buprenorphine offers a relatively mild withdrawal profile; however, it has high affinity 
for, but low intrinsic activity at, µ receptors (NAABT, n.d.).  The µ receptors are targeted 
receptors for endogenous, natural, and synthetic opioids in the brain (Lawrence et al, 2018).  
Such an effect means that the receptor that binds endogenous opioids, (endorphins), and natural 
or synthetic opioids, (morphine or methadone), are displaced by buprenorphine.  Buprenorphine 
will essentially knock off other opioids to occupy the receptor and block other opioids from 
attaching to it (NAABT, n.d.).  As such, the use of buprenorphine while acutely using other 
opioids may cause acute withdrawal symptoms.  However, due to a slow dissociation rate from 
the µ receptor, buprenorphine allows prolonged suppression of opioid withdrawal and such 
properties allow for buprenorphine to be dosed on a less frequent basis once maintenance has 
been established (Center for Substance Abuse Treatment, 2004). 
Although the abuse potential decreases, epidemiological studies and human laboratory 
studies indicate that buprenorphine can be abused (Center for Substance Abuse Treatment, 
2004).  The combination of buprenorphine with naloxone (BUP/NX) helped to minimize abuse 
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potential.  Naloxone, an opioid antagonist, helps to discourage intravenous abuse of 
buprenorphine.  The addition of naloxone precipitates withdrawal in physically dependent 
patients if misused intravenously, however, naloxone’s bioavailability is low if taken as directed 
(NAABT, n.d.).  
The Center for Substance Abuse Treatment (CSAT) Clinical Guidelines for the Use of 
Buprenorphine in the Treatment of Opioid Addiction, published in 2004, remains a relevant 
guideline.  Certain medications and comorbidities may preclude patients as acceptable treatment 
candidates or may require additional monitoring.  Seizure disorders, patients receiving antiviral 
human immunodeficiency virus (HIV) treatment, hepatitis, significant untreated psychiatric 
comorbidities, and pregnancy require careful monitoring and/or consideration for alternative 
treatment (Center for Substance Abuse Treatment, 2004).  Concurrent use of sedatives such as 
alcohol, benzodiazepines, and hallucinogenic drugs may also interfere with treatment adherence 
(Kampman & Jarvis, 2015).  
Buprenorphine, in combination with antiepileptic medications (e.g., phenytoin, 
carbamazepine, and valproic acid) may alter the metabolism of both medications; increasing risk 
for seizure.  As such, therapeutic levels of seizure medications should be monitored (Center for 
Substance Abuse Treatment, 2004).  Similarly, HIV treatment with antiviral medications that 
inhibit, induce, or are metabolized by the cytochrome P450 3A4 enzyme system, may alter 
metabolism of both buprenorphine and the antiviral agent (Center for Substance Abuse 
Treatment, 2004).  However, HIV infected patients have been successfully treated with 
buprenorphine. A study conducted by Carrieri et al. (2000) found no significant short-term effect 
of buprenorphine on HIV viral load in highly active antiretroviral therapy treated patients.  In a 
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more recent study, Altice et al. (2011) concluded, “among those retained on buprenorphine-
naloxone, HIV treatment outcomes did not worsen and were sustained” (p. 6). 
Contraindications include patients with hypersensitivity to buprenorphine or its 
metabolites and patients with severe liver impairment.  In pregnant patients with opioid 
addiction, methadone or buprenorphine as a monotherapy are acceptable treatment options.  
However, the use of combination BUP/NX lacked sufficient evidence for use in pregnant women 
(Kampman & Jarvis, 2015).  
How is Buprenorphine Administered?  
BUP/NX treatment occurs in three phases and includes the induction, stabilization, and 
maintenance phase.  During the induction phase, the patient would ideally have abstained from 
using opioids for 12 to 24 hours as initiation of BUP/NX while having other opioids in their 
system may cause acute withdrawal (SAMHSA, 2016).  Ideally, patients should be in moderate 
withdrawal when administering the first dose.  The use of a standardized, objective measurement 
tool, such as the Clinical Opioid Withdrawal Scale (COWS) reduces bias from patient subjective 
exaggeration of withdrawal symptoms to avoid discomfort (Clinical Tools, Inc., 2018).  See 
Appendix A for an example of the COWS.  
The COWS is an instrument used to evaluate eleven items that include clinical signs and 
symptoms of opioid withdrawal and to make inferences about a patient’s severity of opioid 
dependence (Wesson & Ling, 2003).  It is considered a valid measurement tool for acute opioid 
withdrawal (Altintoprak et al., 2015; Tompkins et al., 2009).  Benefits of the COWS tool include 
rapid administration (<2 minutes), use in the inpatient and outpatient setting, and utilization of 
both subjective and objective findings to reduce patients feigning responses (Wesson & Ling, 
2003).  As buprenorphine may precipitate acute withdrawal if opioids are occupying the mu 
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receptors of the brain, it is important that the patient experience mild to moderate withdrawal 
symptoms (score of > 5 with >10 preferable) prior to induction (mdcalc.com, n.d.).   
According to Kampman and Jarvis (2015), the induction of BUP/NX should start with a 
dose of 2/0.5–4/1 mg sublingual film and may be increased in increments of 2/0.5-4/1 mg 
depending on severity of withdrawal symptoms to a maximum first day dose of 8/2-12/3 mg.  
Although at home induction of buprenorphine outside of the clinic setting is possible, it was not 
considered best practice for new providers to do so (Kampman & Jarvis, 2015).  Instead, the 
initial induction should take place while being monitored within the clinic for 1-2 hours, noting 
any hypersensitivity, withdrawal, or other adverse reactions (Clinical Tools, Inc., 2018).  
On day two of the induction process, the provider may need to increase or decrease the 
dose of BUP/NX based on the patient’s day one reaction.  Patient withdrawal symptoms may 
prompt the provider to add 4/1 mg to the day one dose, with the option of titrating the dose by an 
additional 2/0.5 – 4/1 mg, as necessary.  However, the day two dose should not exceed 16/4 mg. 
Day 3 and up without relief of cravings or experiencing withdrawal symptoms should be given 
an initial dose of 18/4.5 – 20/5 mg sublingually and be increased similarly to day two with a 
maximum dose not exceeding 32/8 mg (Clinical Tools, Inc., 2018 and Center for Substance 
Abuse Treatment, 2004).  However, other literature recommends not exceeding 24/6 mg due to a 
lack of efficacy related to the ceiling effect of the medication (Kampman & Jarvis, 2015).  
“The stabilization phase begins after a patient discontinued or greatly reduced their 
misuse of the problem drug, no longer has cravings, and experiences few, if any, side effects” 
(SAMHSA, 2016, para. 18).  During the stabilization phase, each patient continues the 
determined dose following induction.  According to Kampman and Jarvis (2015), weekly or at 
least bi-weekly office visits that include urine drug screens and pill counts, promote patient 
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compliance.  Dosing of BUP/NX may also be adjusted by 2/0.5–4/1 mg weekly, with most 
patients stabilizing on daily doses of 16/4–24/6 mg, while some patients may require up to 32/8 
mg daily (Center for Substance Abuse Treatment, 2004).  
The maintenance phase is the last stage of the treatment process and may continue 
indefinitely.  However, medication discontinuation, on a predetermined date, is an option if 
mutually agreed upon by patient and provider.  Slowly tapering drug therapy can minimize 
withdrawal symptoms (Center for Substance Abuse Treatment, 2004).  The tapering process may 
take several months to complete.  To support relapse prevention, patients may remain in 
counseling during and after the discontinuation process (Kampman & Jarvis, 2015).  
Unfortunately, relapse rates remain high.  According to Ling et al. (2009), approximately 88% of 
patients have positive urine drug tests three months post-taper.  Nevertheless, relapse and opioid 
use do not result in patient dismissal from the BUP/NX treatment program.  Rather, patient 
relapse triggers reevaluation of the BUP/NX dose, the frequency of office visits, and the 
regularity of behavioral counseling (Clinical Tools, Inc., 2018).  Opioid addiction, not unlike 
other chronic diseases, may relapse, and consequently, treatment modification must follow. 
How does Buprenorphine-Naloxone Efficacy Compare to Other Treatments? 
Comparisons of long-term BUP/NX treatment outcomes with more traditional treatment 
options, such as methadone, lack enough evidence supporting superiority of one treatment 
option.  The success of medication-assisted treatment largely depends on the patient’s individual 
risk factors.  Therefore, patient risk factors and personal preferences are of utmost importance in 
treatment choice.  Srivastava, Kahan, and Nader (2017), found that methadone and BUP/NX 
were both considerably more effective than abstinence-based treatment.  Methadone treatment 
resulted in higher program retention rates, while BUP/NX had a lower risk of overdose.  As 
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such, methadone was preferred for patients at a greater risk of dropouts and patients displaying 
severe withdrawal symptoms and cravings even after reaching optimal BUP/NX doses.  
However, patients at greater risk for methadone toxicity, polysubstance abuse, as well as the 
elderly and patients with a prolonged QT interval should begin treatment with BUP/NX 
(Srivastava, Kahan, & Nader, 2017).  
Hser et al. (2016) also compared mortality rates attributable to MAT programs in the 
United States between 2006 and 2009.  In the study, patients received either buprenorphine or 
methadone for 24 weeks; follow-up interviews occurred in periodic intervals up to an average of 
4.5 years after treatment.  Seven hundred ninety-five participants completed the study (~ 74% 
follow-up rate).  Hser et al. (2016) found no significant differences in mortality between the two 
groups (23 deaths/630 buprenorphine patients versus 26/450 methadone patients).  Few 
differences were found between methadone and buprenorphine treatments and, when compared 
to no treatment, both were associated with less opioid use at follow-up (2016). 
A more recent longitudinal study by Hickman et al. (2018) compared all-cause mortality 
and opioid drug‐related poisoning mortality between methadone with buprenorphine in the 
United Kingdom.  Patients on buprenorphine had lower rates of all-cause mortality and opioid 
drug-related poisonings at each treatment period.  However, the treatment duration (mean and 
median) was much shorter than that of methadone (173 and 40 versus 363 and 111, respectively) 
(2018).  The study speculated the short duration of treatment with buprenorphine and the higher 
mortality risk after treatment cessation may indicate that neither buprenorphine nor methadone 
are particularly effective in limiting drug-related poisonings (Hickman et al., 2018).  However, 
as noted previously, the maintenance phase of buprenorphine treatment is not limited and may 
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continue indefinitely or until a patient feels, they are ready to wean off the medication (Center 
for Substance Abuse Treatment, 2004). 
Patient preference regarding MAT for OUD is important to consider.  Patients who 
received BUP/NX reported a more positive treatment experience compared to patients treated 
with methadone (Hill et al., 2015).  Respondents described a feeling of being clear-headed, 
improvement in general well-being and concentration, less social stigma, reduced craving, 
decreased side effects, and easier withdrawal from BUP/NX vs. methadone (Hill et al., 2015).  
Patients’ also described treatment in primary care settings as a more convenient and therapeutic 
environment for sobriety and relapse prevention while experiencing more respect, trust, and 
empathy from providers (Jenkinson and Ravert, 2013).   
What are the Barriers to Buprenorphine MAT? 
Several barriers limit the number of patients able to receive MAT with BUP/NX.  In a 
study by Hutchinson et al. (2014), 120 physicians working in Washington State, received 
training and earned a waiver to prescribe buprenorphine.  Nearly all 78 physicians who 
responded to interviews (and had not previously been prescribing buprenorphine or were not in 
their residencies) had a positive attitude toward MAT.  However, only 22 of the physicians 
actively prescribed buprenorphine, with 95% (21/22) of the physicians practicing in a family 
medicine setting.  Some of the barriers described by the physicians included a lack of 
institutional support, lack of office partners who also prescribed buprenorphine, lack of mental or 
psychosocial support for patients, time constraints, and a general lack of confidence in their 
ability to manage this population of patients (Hutchison et al, 2014).  
Similar provider barriers were common among other studies.  Indeed, DeFlavio, Rolin, 
Nordstrom, and Kazal Jr. (2015) found that barriers for rural physicians in New Hampshire and 
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Vermont included a lack of knowledge, time, space, or interest; mistrust of people with addiction 
or buprenorphine as a treatment; burdensome regulations and a difficult patient population.  
However, the majority (70%) of respondents felt a responsibility to treat opioid addiction among 
patients seen in the primary care setting (2015). 
The results of a national study of rural physicians identified many of the same provider 
barriers as described above (DeFlavio, Rolin, Nordstrom, and Kazal Jr., 2015 and Hutchison et 
al, 2014).  Interestingly, physicians who had never prescribed, but held a buprenorphine waiver, 
identified prescribing barriers with greater frequency compared to physicians who actively 
prescribed buprenorphine.  Such barriers included time constraints, lack of patient need, 
resistance from practice partners, lack of specialty backup for complex problems, lack of 
confidence in their ability to manage OUD patients, concerns about DEA intrusions on their 
practice, and attraction of drug users to their practice (Andrilla, Coulthard, and Larson, 2017).  
A study by Marino, Campbell, and Nunes (2016) also found that lack of knowledge, time 
constraints, access to ancillary support (mental health services), lack of other prescribers, lack of 
space, and lack of reimbursement were commonly cited barriers.  Not only did the physicians 
consider treating addicted patients time consuming, the unique aspects of the care required 
proved difficult to incorporate in the primary care setting (2016).   
Finally, according to Jones, Campopiano, Baldwin, and McCance-Katz (2015), 
“Consistently identified barriers included willingness to prescribe, low provider confidence in 
addressing addiction, limited access to addiction experts, lack of institutional or office support, 
lack of behavioral health services, and reimbursement concerns” (p. e55).  Development of a 
clinic-based BUP/NX MAT program at the PCC may benefit from understanding common 
prescribing barriers.   
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Theoretical Framework: Social Ecological Model 
The development of a BUP/NX MAT program in the primary care setting required a 
multifocal, multidisciplinary approach.  The Social Ecological Model (SEM) is a theory-based 
framework for understanding the multilayered and collaborative effects of personal and 
environmental influences that determine behaviors (Glanz, 2016).  The principles of the theory 
suggested that creating an environment conducive to change is important to making it easier to 
adopt healthy behaviors (Glanz, 2016).  According to the United Nations Children's Fund 
(UNICEF), the SEM provided guidance for developing successful programs through social 
environments, identifying behavioral and organizational influences, and mediating health 
promotion within organizations.  Included in the model were five levels of influence: individual, 
interpersonal, organizational, community, and policy, with effective approaches to public health 
prevention and maintenance incorporating all levels (2015).  
1. Individual: Regards the patient, their knowledge, attitudes, behavior, gender, age, 
religious identity, racial/ethnic identity, sexual orientation, economic status, values, 
goals, expectations, literacy, stigmas, and other factors may all occupy the individual 
level.  Providers’ feelings and beliefs about treating OUD with MAT for OUD is an 
important consideration.   
2. Interpersonal: At the interpersonal level, friends, family, and health care providers help 
overcome individual-level barriers by affecting social and cultural norms.  The stigma of 
addiction and addiction treatment, may “contribute to social isolation, reduce help-
seeking behaviors, and undermine long-term recovery” (Jones, Campopiano, Baldwin, & 
McCance-Katz, 2015, p. e58).  
 19 
3. Organizational: Facilitates individual behavior change with organizational systems and 
policies, which can affect how well services are provided.  Organizational support is 
essential for the success of the program because lack of institutional support was a 
frequently cited barrier to prescribing BUP/NX (Andrilla, Coulthard, & Larson, 2017; 
Hutchinson, et al., 2014; Jones, Campopiano, Baldwin, & McCance-Katz, 2015; Marino, 
Campbell, & Nunes, 2016).  
4. Community: The community level involved cooperation and support between 
community institutions by providing and sharing communication, services, and resources.  
The community level included members of the community who share the concerns about 
a given public health topic.  The level included law enforcement, healthcare institutions, 
city and state government, community groups and organizations such as the CDRC.  To 
make an impact on the opioid epidemic, a multidisciplinary team with community 
support was necessary.  An additional resource could include the Minnesota and ND 
prescription-monitoring program.  
5. Policy: The policy level involves local, state, national, and global laws and policies, 
including those concerning the allocation of resources and services.  For example, 
interpreting and implementing existing policy such as the expansion of prescriptive 
privileges to nurse practitioners and physician assistants through the DATA 2000 and 
CARA.  
The use of the SEM presented the unique ability to address the multi-layered nature of 
opioid addition and to provide an individualized, yet structured approach to treatment.  Instead of 
focusing solely on individual-level factors, the interplay between the different ecological levels 
may enhance treatment outcomes.    
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CHAPTER THREE. PROJECT SIGNIFICANCE, DESIGN, AND IMPLEMENTATION  
Significance 
The Fargo-Moorhead community lacked primary care opioid use disorder BUP/NX 
treatment options; however, there were a few private practice facilities and one methadone-
dispensing clinic.  Members from a primary care clinic (PCC) and chemical dependency 
residential center (CDRC) joined forces to provide a comprehensive treatment program for 
OUD.  
Education was an integral component to the success of the program.  A frequently cited 
barrier to prescribing buprenorphine was a lack of knowledge or ability to manage OUD or 
addicted patients (Hutchinson, et al., 2014).  Several studies also indicated a lack of providers 
willing to prescribe MAT and organizational support were common barriers (Andrilla, 
Coulthard, & Larson, 2017; Hutchinson, et al., 2014; Jones, Campopiano, Baldwin, & McCance-
Katz, 2015; Marino, Campbell, & Nunes, 2016).  Nurse practitioners could obtain a waiver to 
prescribe buprenorphine for up to 30 patients (in year one) through SAMHSA after 24 hours of 
training (8 hours of which is specific to safe medication prescribing) (American Society of 
Addiction Medicine, 2018).  Formal training was necessary to prepare NPs for the challenges of 
working with an opioid addicted patient population and unique treatment program. 
Lack of mental health or specialty services was a frequently mentioned concern of 
providers (Andrilla, Coulthard, & Larson, 2017; Hutchinson, et al., 2014; Jones, Campopiano, 
Baldwin, & McCance-Katz, 2015; Marino, Campbell, & Nunes, 2016).  Some studies indicated 
neutral benefit of behavioral therapy with buprenorphine retention rates (Fiellin et al, 2013; Ling 
et al., 2013; Weiss et al, 2011).  However, provider comfort in utilizing mental health/addiction 
services to work with their patients’ psychosocial concerns may aid in provider comfort to 
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continue prescribing BUP/NX.  An interprofessional relationship with a behavior and licensed 
addiction service provider may benefit a primary care clinic when serving the OUD patient 
population. 
An agreement was reached between the PCC and CDRC to develop a MAT program for 
OUD.  After brainstorming with both facilities, the current project resulted.  The following 
section will briefly describe the services of both the PCC and the CDRC.  The creation of a 
BUP/NX MAT program will be subsequently discussed along with ways to manage potential 
barriers. 
Primary Care Clinic and Chemical Dependency Residential Center 
The PCC is a family-oriented health care clinic serving the Fargo-Moorhead area.  The 
clinic provides a wide variety of services including medical, dental, pharmaceutical, nutrition, 
vision, physical therapy, laboratory, X-ray, homeless health, and behavioral health services.  All 
patients are accepted regardless of ability to pay or insurance status; allowing a greater number 
of underserved patients eligible to receive MAT for opioid addiction.  
The PCC offers patients federally qualified discount opportunities to assist patients in 
accessing affordable healthcare.  The Access Plan is a sliding scale fee program that provides 
discounts on medical, dental, and prescription services based on household size and gross 
income.  Patients are eligible if their income does not exceed 200% of the Federal Poverty 
Guidelines and patient financial eligibility is reviewed annually.  An Access Plan application is 
completed each year and a PCC representative determines the patient/family eligibility status 
(_____________ Access Plan, 2017).   
The CDRC offers residential and nonresidential chemical dependency evaluation and 
treatment as well as mental health services in the Fargo-Moorhead area.  The services offered by 
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CDRC are diverse and include, but are not limited to, mental health diagnostic assessments, 
individual and group therapy, DUI educational seminars, narcotics anonymous (NA) groups, 
relapse prevention groups, and more.  CDRC does not offer MAT for opioid addiction, however, 
management agreed to collaborate with the PCC to provide the service to CDRC residents.  
Congruence of the Project to the Organization’s Strategic Goals 
The PCC’s mission was to provide affordable, comprehensive care for individuals, and to 
improve the health of the community.  An organizational priority became enhancing access to 
opioid addiction treatment in the Fargo community and surrounding metropolitan area.  The 
BUP/NX treatment program spoke to the mission and philosophy of the organization.  The 
combination of services of PCC and the CDRC allowed each facility to contribute expertise in 
medical care and mental health services to provide comprehensive care for patients with OUD. 
Project Design 
The program incorporated the Plan, Do, Study, Act (PDSA) framework.  PDSA is a 
quality improvement tool for implementing changes on a small scale, analyzing the results, and 
then acting on what was learned (HHS, 2013).  Plan involved the project design, Do involved the 
project implementation, Study involved the project evaluation, and Act included 
recommendations for future study.  The framework worked well with the mission of the PCC and 
objectives set forth which aimed to improve access to opioid addiction treatment.   
The project was a new concept in the treatment of OUD in the Fargo-Moorhead 
community.  Traditional methods to treat OUD, such as methadone clinics, as well as private 
treatment programs were available.  However, no outpatient clinic in the city had developed a 
primary care model utilizing BUP/NX for outpatient OUD treatment.  A program of this degree 
required a great deal of planning and several steps were necessary prior to project initiation.   
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Between March 2018 and May 2018, discussion of an evidence-based BUP/NX program 
was discussed between members of the PCC.  Determination of needs was established and 
networking with additional community organizations including the CDRC began May 2018 
through September 2018.  The initial literature review of BUP/NX use in primary care was 
completed between June 2018 and October 2018.  Networking with CDRC representatives and 
PCC representatives to discuss necessary forms and other project needs occurred September 
2018.  Providers at the PCC completed the mandatory 24-hour training to receive a 
buprenorphine prescription waiver through the Department of Vermont Health Access in 
Vermont between June 2018 and September 2018.  IRB approval and project official start date 
occurred November 14, 2018.   
Five PCC nurse practitioners received 24-hours of training to apply for a DATA waiver 
to treat up to 30 patients the first year and a new Drug Enforcement Agency (DEA) number.  
Development of treatment guidelines specific to PCC, consent forms, and a provider order-set 
were created.  Nurses were trained in the use of the COWS scoring tool while recruitment of 
BUP/NX participants fell on the CDRC to refer eligible patients.   
Patients received addiction counseling and case management services at the CDRC while 
NPs at the PCC provided medication assistance to promote retention of patients and to prevent 
relapse.  The CDRC referred patients to the PCC who desired treatment with BUP/NX and met 
the ASAM criteria for OUD.  A licensed addiction counselor provided the diagnosis to OUD 
prior to the patient’s referral to the PCC.  Appointment scheduling and coordination of 
transportation were the responsibility of CDRC employees.  PCC NPs each assumed medical 
responsibility for no more than five new BUP/NX patients during the pilot program.  
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Upon diagnosis of OUD, the CDRC referred patients to the PCC who desired treatment 
with BUP/NX MAT and did not have severe concurrent addiction to alcohol, methamphetamine, 
or benzodiazepines, severe mental health disorders that would impair their ability to take 
BUP/NX, or patients under 18 years of age.  Appointment scheduling and coordination of 
transportation was the responsibility of CDRC employees.  Commonly, transportation was 
provided through the City of Fargo Metro Area Transit bus system, which was unable to bring 
the patients directly to the clinic but was able to bring them within a couple blocks of the clinic.  
Addiction specialists at the CDRC provided their recommendation for referral to the PCC; 
scheduling coordinators at the PCC scheduled patients to establish care with a primary care 
provider trained in prescribing MAT with BUP/NX.  Nurses roomed the patients and provided 
the treatment agreement form as well as the consent for treatment with BUP/NX.  Next, the NP 
assessed the patient, reviewed the consent forms, and explained the process of induction.  A 
COWS baseline score was gathered.  If additional laboratory tests were indicated, the NP placed 
the order by utilizing the new patient evaluation order-set in Centricity (the electronic medical 
record utilized at the PCC).  Inductions took place in the clinic.  PCC NPs each assumed medical 
responsibility for no more than five new BUP/NX patients during the pilot program. 
The objective was to deliver high quality, focused care to a larger number of patients 
participating in the MAT program.  Limiting treatment time to one day per week was considered 
too large of an obstacle during the induction phase, which requires frequent visits and close 
monitoring for adverse reactions and effective dosing (Clinical Tools, Inc., 2018).  Through 
discussions with the project team, the practical solution, at least during induction, was to 
incorporate MAT into everyday practice.  
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Consent for treatment, provider order-set, and treatment guidelines streamlined the 
evaluation and treatment process.  Treatment guidelines consisted of, but were not limited to, 
qualifications for treatment, utilizing the COWS for opioid withdrawal scoring, initial BUP/NX 
dosing, and prescribing of BUP/NX once the induction phase had ended. Guidelines were 
derived from the Center for Substance Abuse Treatment clinical guidelines for the use of 
buprenorphine in the treatment of opioid addiction (2004) and Vermont buprenorphine clinical 
practice guidelines (2015).  Exclusions for treatment included severe addiction to additional 
substances such as methamphetamine, alcohol, or benzodiazepines, severe mental health 
disorders or cognitive impairment, or patients under 18 years of age.  An example of the 
buprenorphine/naloxone consent and agreement form is in Appendix B.  Provider order-set 
included orders for referrals to the CDRC for continuation for counseling, urine drug screen 
collected either at the PCC or CDRC, comprehensive metabolic panel, hepatitis C Ab with reflex 
to hepatitis C PCR, hepatitis B surface antigen, hepatitis B surface antibody, HIV 1 Ag HIV ½ 
Ab with reflex to confirmation, hepatic panel, and urine HCG.  Provider order-set was imported 
into the Centricity electronic medical record system.  The project start date was November 14, 
2018.  
Financial reimbursement for services rendered, dispensing of buprenorphine through the 
PCC pharmacy, and assistance in enrolling patients in an Action Plan were determined prior to 
seeing patients but were not the responsibility of the project.  Other details including number of 
patients treated by each provider, observation space, and roles of supporting staff such as 
registration personnel and nurses were defined by their respective organizations. 
Financial reimbursement was complicated and may be multifactorial.  The cost of 
BUP/NX medication was covered by the 340B Drug Pricing Program, which offers discounted 
 26 
prices on medications as part of a Medicaid rebate program (340bhealth.org, 2018).  The patient 
cost of BUP/NX was no greater than the clinic’s purchase price.  Patients who were on the 
Action Plan or who had insurance but still fell below the poverty level could use the 340B 
discount program.  However, the financial implications were complex and beyond the scope of 
the project. 
Stakeholders 
Stakeholders in the project included representatives from the CDRC such as counselors, 
case managers, the clinical director, and the CEO.  Shareholders from the PCC included the 
medical director, nurse practitioners, nurses, appointment schedulers, pharmacists, and financial 
enrollment staff.   
Project Implementation 
The implementation of the project constituted the “Do” phase of the PDSA.  Official 
project start date followed approval by the Institutional Review Board (IRB) of North Dakota 
State University (NDSU) on November 14, 2018.  Five NPs completed the required 24-hours of 
training to receive a buprenorphine prescriptive waiver prior to the project start date.  Additional 
training in utilizing the COWS was completed by nurses at the PCC during a brief, 10-minute in-
service discussion on February 4, 2019.  The presentation took place during the nurses’ monthly 
meeting and consisted of a brief overview of COWS scoring, the purpose of the scale, and other 
subjective and objective aspects to consider while assessing opiate withdrawal.  An example of 
the COWS was distributed to the attendants in order to follow along with a PowerPoint 
presentation.  Presentation of the COWS tool is found in Appendix H.   
BUP/NX MAT guidelines, consent for treatment, and a provider order-set were utilized 
on November 14, 2018 to navigate the evaluation and treatment process.  An example of the 
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BUP/NX consent and agreement form is in Appendix B.  The consent for treatment forms and 
provider order-set were distributed on August 22, 2019 to the medical director and NPs who had 
completed the required BUP/NX training.  Additionally, the clinical service manager and a nurse 
at the PCC received the documents who had completed independent research by touring the 
CDRC and methadone clinic in Fargo, ND.  They edited the consent forms and order-set to better 
reflect the needs of the PCC, which were approved on September 24, 2019 by the PCC 
stakeholders.  Due to the timeline needs of the PCC, the forms were completed prior to the 
project start date.  However, the initial confidence survey was distributed on November 16, 2018 
to NPs at three clinic locations in Fargo, ND and West Fargo, ND.  Post-implementation 
confidence surveys were distributed on January 28, 2019 during a MAT provider meeting at the 
PCC.  Additionally, qualitative, open-ended questionnaires were dispersed at the same time as 
the post-implementation confidence surveys. 
Institutional Review Board Approval 
No patient contact was required to fulfill the objectives of the project.  The project did 
not involve interviewing patients and no patients are identified in the evaluation.  Additionally, at 
no time were provider’s personal information collected or accessed.  This practice improvement 
project was considered exempt by the NDSU IRB in accordance with federal regulations on 
November 14, 2018.  The exemption letter is in Appendix I.  
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CHAPTER FOUR. EVALUATION  
The “Study” component of the PDSA comprised the evaluation of the project.  The plan 
for project evaluation utilized initial and post-implementation surveys to evaluate NP confidence 
in providing MAT as well as a qualitative questionnaire to evaluate strengths and weaknesses of 
the program.  Likert scale survey scores averaged, and questionnaire responses coalesced by the 
author.  
Objective 1 Evaluation 
Objective 1: Evidence-based guidelines, consent for treatment forms, and a provider 
order-set necessary for MAT program implementation are completed prior to program 
implementation.  Guidelines, consent forms, and provider order-set developed using 
recommendations from the Department of Vermont Health Access Managed Care Entity’s 
Vermont Buprenorphine Clinical Practice Guidelines, Center for Substance Abuse Treatment 
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction 
Treatment Improvement Protocol (TIP) Series 40, and American Society of Addiction Medicine 
National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving 
Opioid Use.  Objective 1 evaluation consisted of review and approval of the treatment 
guidelines, consent forms, and provider order-set by representatives of the PCC prior to 
implementation.  
The consent for treatment forms and provider order-set were distributed on August 22, 
2019 to the medical director, NPs, clinical service manager, and a nurse at the PCC.  The clinic 
service manager and a nurse revised the forms to fit the needs of the PCC.  The PCC 
stakeholders approved the two consent for treatment forms and the provider order-set on 
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September 24, 2019.  Paper copies of the consent forms were kept at the PCC.  Once the patient 
signed the document, the consent forms were placed in a patient’s medical file.  
Objective 2 Evaluation 
Objective 2: Prior to implementation, nurses at the PCC are knowledgeable about and 
successfully using COWS.  Use of the COWS tool presented to nurses at the PCC during their 
monthly meeting.  Evaluation of objective 2 consisted of immediate verbal feedback collected 
following the presentation in an open forum construct.  
Objective 3 Evaluation  
Objective 3: PCC nurse practitioners will feel confident in treating OUD using BUP/NX 
MAT.  Evaluation of NP confidence consisted of provider confidence surveys administered at 
the start of project implementation and two months post-implementation.  A 5-point Likert scale 
reflecting the response categories of strongly agree, agree, undecided, disagree, strongly disagree 
was used.  The survey consisted of 15 statements created to evaluate the various determinants 
that affect provider confidence in MAT.  Statements also evaluated common barriers associated 
with providing MAT for OUD.  The provider confidence surveys were distributed along with a 
plain manila envelope.  The NPs returned the surveys to the manila envelope and the co-
investigator collected the envelopes.  The NPs were asked not to sign their names to protect 
anonymity.  An example of the survey is in Appendix C.  The statements within the survey were 
original and did not come from a previously utilized survey.   
Surveys and questionnaires were stored at the PCC after completion and picked up within 
24-hours by the investigator in their sealed manila envelopes.  Once collected and the data 
reviewed, the unused forms were again sealed in a manila envelope and placed in a locked area 
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for secure storage within the investigators home.  No other person had access to the completed 
forms aside from the investigator.    
Objective 4 Evaluation 
Objective 4: At 2 months post-implementation, providers are able to identify program 
strengths and weaknesses.  Evaluation of objective 4 was via a questionnaire and confidence 
survey.  As previously, NPs received the questionnaire and survey in individual manila 
envelopes and the coinvestigator collected the envelopes with the completed documents.  There 
were no identifying marks on the envelope or the completed forms for respondent anonymity.  
The questionnaire consisted of nine open-ended questions designed to elucidate the perceived 
strengths and weaknesses of the project.  An example of the questionnaire is in Appendix F.  
Like the confidence survey, the questionnaire did not originate from a previously utilized 
questionnaire.  
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CHAPTER FIVE. RESULTS 
Demographics 
The sample size consisted of five NPs who completed the initial survey and four NPs that 
completed the two-month post-implementation survey.  All five NPs were female.  Professional 
experience as a NP ranged between 3 and 11 years.  No additional demographic information was 
collected. 
Objective 1 Results: Project Forms and Provider Order-Set 
Objective 1: BUP/NX guidelines, consent for treatment form, treatment agreement form, 
and provider order-set were finalized prior to program implementation.  The PCC administration, 
NPs, clinical service manager, and nurses reviewed the forms August 22, 2018.  The clinical 
service manager and PCC nurse amended the documents September 24, 2018 to better reflect the 
needs of the clinic.  The NPs used the guidelines, consent form and treatment agreement form, 
and the provider order-set during the MAT project starting November 16, 2018.  An example of 
the consent form and treatment agreement is in Appendix B, Appendix C, and Appendix D.  The 
provider order-set is in Appendix H.   
Objective 2 Results: COWS Tool Presentation 
Objective 2: Prior to implementation, nurses at the PCC are knowledgeable about and 
successfully using COWS.  The objective was not met.  The PCC nurses were not using the 
COWS tool prior to project implementation on November 14, 2018.  The COWS presentation 
occurred on February 4, 2019 at the PCC in Fargo at 12:00 pm.  The presentation lasted 
approximately 10 minutes.  Fourteen nurses attended the presentation.  The nurses provided 
verbal feedback via an open forum, question-answer type format following the presentation.  
Prior to the presentation, three nurses were familiar with the COWS, while the remaining eleven 
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were introduced to the content for the first time at the presentation.  The nurses expressed an 
interest in using COWS, however, they were concerned about using COWS in the clinical setting 
without additional training. 
Objective 3 Results: Provider Confidence Surveys 
Nurse practitioner confidence was measured pre and post project implementation by a 5-
point Likert scale survey.  The Likert scale responses consisted of strongly agree (5), agree (4), 
undecided (3), disagree (2), and strongly disagree (1).  Results averaged and are in Table 1.  
Baseline confidence survey N=5.  Post-implementation confidence survey N=4.  One statement 
was not answered in the post-implementation confidence survey.  The response rate was 100% at 
baseline and 80% post-implementation.  
Table 1 
   
Provider Confidence Survey 
 
   
Statements 
Baseline 
N=5 
Post 
N=4 
Diff 
1. I view opioid addiction as a chronic disease.   4.2 4.3 0.1 
2. I can identify resources in the community to aid in addiction therapy. 4.0 4.5 0.5 
3. I can identify specialty services for complex comorbidities.  4.0 4.3 0.3 
4. I feel knowledgeable regarding the pathophysiology of opioid abuse.  3.8 4.5 0.7 
5. I am willing to provide medication assisted treatment (MAT) for opioid 
use disorder (OUD). 
4.6 4.8 0.2 
6. I am confident in my ability to identify opioid abuse among my patients. 3.8 4.3 0.5 
7. I am confident in my ability to manage patients with MAT for opioid 
abuse.  
3.4 3.8 0.4 
8. The organization that I work for helps support my efforts to treat OUD.  4.8 4.8 0.0 
9. I can identify fellow providers who provide MAT with 
buprenorphine/naloxone for OUD.  
4.2 4.8 0.6 
10. I feel that there is resistance from my associates or place of work to 
continue/start MAT for opioid addiction.  
1.2 1.8 0.6 
11. I am hesitant to prescribe buprenorphine/naloxone due to prescription 
misuse or diversion.    
2.8 2.5 -0.3 
12. I am hesitant to prescribe buprenorphine/naloxone due to concerns about 
cost reimbursement. 
1.6 1.5 -0.1 
13. I believe that I have enough time during office visits to address my 
patient’s addiction treatment.    
2.4 2.8 0.4 
14. I am comfortable talking about opioid abuse/addiction with my patients. 4.4 4.5 0.1 
15. I would feel more confident in providing MAT for OUD if my patient is 
also receiving addiction counseling.  
4.8 4.8 0.0 
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The statements on the provider surveys may be organized into four themes, which include 
confidence or lack of confidence, knowledge, willingness, and perception.   
Theme 1: Confidence 
Statements 6, 7, 14, and 15 are measurements of provider confidence while statements 11 
and 12 relate to the provider hesitance or lack of confidence.  Nurse practitioners indicated 
feeling considerably more confident identifying opioid abuse and in managing patients treated 
with MAT two months post-implementation.  Nurse practitioner confidence in discussing abuse 
and addiction with patients slightly increased.  The purpose of statements 11 and 12 was to 
inquire about provider hesitancy in prescribing MAT due to fear of patient misuse, diversion, or 
because of reimbursement concerns.  Statement 11 and 12 responses decreased two months post-
implementation, which would suggest an increase in provider confidence.  
Theme 2: Knowledge 
Statements 2, 3, 4, and 9 pertain to knowledge about opioid addiction and community 
resources.  At two months post-implementation, NPs felt more knowledgeable about community 
addiction resources, other MAT providers, as well as specialty care for patients with comorbid 
illnesses.  The largest increase in mean scores was in NP perceived knowledge about the 
pathophysiology of opioid addiction.  The baseline mean of 3.8 falls in to the undecided to agree 
range, while the post-implementation mean of 4.5 was in the agree to strongly agree range. 
Theme 3: Willingness 
Statement 5 related to NPs willingness to provide MAT to OUD patients.  Nurse 
Practitioners were just slightly more willing to provide MAT to OUD patients when surveyed 
post implementation.  Baseline and post implementation scores were both in the strongly agree 
range (4.6, 4.8 respectively). 
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Theme 4: Perception 
The four statements pertaining to provider perception were 1, 8, 10, and 13.  Nurse 
Practitioners’ perceived slightly less resistance from their associates about the MAT program.  
Furthermore, NPs strongly agreed that the PCC supported the MAT program, and the perception 
of organizational support did not change over the two months.  The NPs perception of having 
enough time with the patient increased from baseline.  Finally, the NPs believed that opioid 
addiction is a chronic disease, and there was only a minute increase in that belief. 
Objective 4 Results: Qualitative Provider Questionnaire 
The questionnaire was administered with the NP confidence surveys at the January 28, 
2019 provider meeting, two months after program implementation.  The qualitative questionnaire 
consisted of nine open-ended, short answer questions.  Four NPs completed the questionnaire 
(response rate of 80%).  Responses were randomized to decrease the possibility of identifying 
the respondent.  Responses are in Table 2.  
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Table 2 
Provider Interview Questions and Responses  
 
Qualitative Interview Question Provider Responses 
What do you perceive as the strengths of the 
program? 
Access to medical care by accepting patients without health insurance.  
Utilizing the Action Plan sliding scale fee to assist with patient’s ability to 
pay. 
Treatment that allows more normalized routine such as work, family, and 
other responsibilities.  
Patient comfort receiving treatment in an office setting. 
Support from providers, clinic staff and addiction counselors at the CDRC. 
What are the weaknesses of the program? Lack of addiction counselor within the PCC.  
Inexperience with treating OUD patients. 
Lack of rapid, inhouse drug testing and nursing staff to support expanded 
MAT program.  
Only taking referrals from one facility (CDRC). 
What are your opinions about the referral 
process and relationship with CDRC 
employees? 
Knowledgeable and good communication. 
Good working relationship.  
Having a counselor on site may limit miscommunications.  
What have been the biggest barriers for 
providers and the clinic in first three months 
of the program? 
Proper dosing 
Assessing appropriateness for outpatient treatment  
Getting patient set up for outpatient treatment  
Informing the community about MAT service 
Not enough experience due to low patient volume 
Do feel the evaluation process is 
comprehensive and meets the needs of 
providers, the clinic, and the patients? 
Explain your answer. 
CDRC does initial evaluation prior to referral which can lead to some 
miscommunication and discrepancies.  
Both providers and patients seem satisfied with the evaluation and treatment 
process.  
CDRC provides some formal education.  
What is your current patient load and what do 
you believe is an acceptable patient load 
going forward? 
Between 0-5 patients 
Acceptable patient loads vary, but providers managing a greater number of 
OUD patients list a higher number of acceptable patients. Some providers are 
not able to give a definitive number, while others feel between 5 and 20 is 
acceptable. 
What factors have promoted patient retention 
in the program? 
Availability and access to other services 
Supportive environment  
Commitment to recovery and following contract/guidelines.  
Have you found the program forms or 
evaluation tools lack clarity? If so, how? 
Forms are acceptable and do not lack clarity.  
However, forms are long, and patients may not read them carefully or 
understanding them, especially if they are going through withdrawal.  
What recommendations for improvement 
would you like to see made to the program? 
In-house counselor 
Case manager to follow-up with patient compliance  
Better understanding of which patients are outpatient appropriate and which 
need more complex care.  
More general in-house support services.  
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CHAPTER SIX. DISCUSSION AND RECOMMENDATIONS 
Interpretation 
The purpose of the project included development of an evidence-based BUP/NX MAT 
program and evaluation of NP confidence in providing MAT for OUD patients.  The NPs 
responses on the two questionnaires were generally positive two months after project 
implementation.  Overall, the NPs felt more confident, knowledgeable, and supported by clinic 
administration and staff in treating patients with an opioid addiction.  Additionally, NPs were as 
willing to participate in MAT at two months post-implementation as they were at baseline.  
Objective One: Project Forms and Provider Order-Set 
The first objective was met.  An evidence-based treatment guideline, provider order-set 
and patient consent for treatment form were developed and subsequently reviewed on August 22, 
2018 and approved on September 24, 2018.  The clinical service manager and nursing staff   
customized the forms for PCC, with only minor revisions of the original forms.  Forms were 
available for use at the PCC/CDRC MAT for the OUD program on November 16, 2018.  See 
Appendixes for approved documents. 
The PCC NPs felt that the forms were very thorough, but time-consuming.  To maximize 
NP/patient face-to-face time, the staff discussed having the patient complete the consent forms 
prior to seeing the NP.  Staff also expressed concern about the patients’ understanding of the 
consent form while experiencing opioid withdrawal symptoms in the induction phase of 
treatment.  Forms should be reviewed and updated annually and as the need arises.  The date of 
each revision should be added to the form.  Perhaps, the forms, guidelines, and provider order set 
could be shared as a blueprint for the implementation of a BUP/NX MAT program at other 
clinics.  
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Objective Two: COWS Tool Presentation 
Objective 2 was not met; the nursing education on the COWS assessment tool (Appendix 
A) did not occur prior to project implementation in November, rather, the educational 
presentation was on February 4, 2019.  Because the nurses had not received the training, the tool 
was not used consistently during the first several months of the program.  Due to the short 
allotment of time scheduled for COWS education (10 minutes), an in-depth discussion on each 
assessment category of the tool was not possible.  Nurses provided feedback in an open forum 
question-answer format post-presentation.  The feedback from nurses was generally positive.  
Ideally, more time should have been allocated for the education.  I would recommend a 
minimum of 30 minutes to allow time for nurses to practice, or role-play with the COWS tool.  
PCC nurses are familiar with a variety of assessment tools.  It would not be difficult to envision 
nurses using the COWS during OUD patient inductions.  Nurses expressed interest in utilizing 
the COWS but also expressed concern about using COWS without additional training.  
Additional in-service training would be beneficial for the PCC nurses to familiarize themselves 
with the COWS.  The provider qualitative questionnaire (objective 4) reaffirmed the need for 
knowledgeable staff to support the MAT program.  Nurses’ use of the COWS to assess for 
opioid withdrawal symptoms may improve quality of care by providing an evidence based 
standardized assessment of the patient.   
Objective Three: Provider Confidence Surveys 
Objective three was created to evaluate NP confidence at project initiation and two 
months post-implementation.  The survey tool can be found in Appendix D.  Five NPs completed 
the initial survey while four NPs completed the two-month post-implementation survey.  One NP 
left one statement unanswered in the post-implementation survey.  
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Theme 1: Confidence 
Statements 6, 7, 14, and 15 are measurements of NP confidence while statements 11 and 
12 relate to the NP hesitance or lack of confidence.  Nurse Practitioner confidence improved or 
remained the same at the two-month mark.  Statements 11 and 12 inquired about provider 
hesitancy in prescribing MAT due to fear of patient misuse, diversion, or because of 
reimbursement concerns.  
Statement 11 and 12 responses decreased two months post-implementation.  Responses 
may suggest an increase in NP confidence managing OUD patients.  The decreased risk of 
overdose with BUP/NX and coordination with the CDRC for drug testing, close follow-up, and 
counseling may have been positive influences in provider responses.  Cost reimbursement does 
not appear to be a frequent concern, which may be due to the medication coverage through the 
340B Drug Pricing Program and patient enrollment in the PCC Action Plan.  
Statement 6 and 14 responses may have been due to conversing with patients regarding 
addiction experiences, NP prescriptive waiver training, application in practice, and use of the 
COWS tool.  Nurse Practitioner confidence in managing patients with MAT for OUD (Statement 
7) improved post-implementation but was still categorized as undecided.  Some NPs lack of 
opportunity to manage OUD patients with MAT during the project may have influenced the 
responses. 
Statement 15 responses did not change as NPs strongly agree that they would feel more 
comfortable treating OUD if patients were also receiving addiction counseling.  Nurse 
Practitioners may have felt encouraged by the support of another organization to address the 
mental health aspect of addiction and be more willing to become MAT prescribers. 
 39 
Theme 2: Knowledge 
Statements 2, 3, 4, and 9 pertain to knowledge about opioid addiction and community 
resources.  At two months post-implementation, NPs felt more knowledgeable about community 
addiction resources, other MAT providers, as well as specialty care for patients with comorbid 
illnesses.   
The largest increase in mean scores was in NP perceived knowledge about the 
pathophysiology of opioid addiction (Statement 4).  The baseline mean of 3.8 falls in to the 
undecided to agree range, while the post-implementation mean of 4.5 was in the agree to 
strongly agree range.  Education and training to acquire a buprenorphine prescriptive waiver, 
along with application of training in practice, may have influenced NP responses.   
Nurse Practitioners more strongly agreed post-implementation that they could identify 
community resources to aid in addiction therapy (Statement 2).  The response may have been due 
to working with the CDRC.  Nurse Practitioners may consider their partnership with the CDRC, 
which provides addiction counseling, as one of the new community resources.  Responses to 
Statement 3 also improved two months post-implementation, which may have been due to NPs 
attributing specialty services with addiction counseling, familiarity with the referral process, and 
managing OUD patients.  Additionally, NPs more strongly agreed they could identify fellow 
providers who prescribed BUP/NX to treat OUD (Statement 9).  Each NP in the project had 
completed the required 24-hour training to receive a buprenorphine prescriptive waiver.  
Providers also attended mandatory meetings help by the PCC each month, during which time the 
topic of BUP/NX MAT was discussed.  Due to proximity and familiarity, providers may not 
have found it difficult to identify additional MAT prescribers.   
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Theme 3: Willingness 
Statement 5 related to NPs willingness to provide MAT to OUD patients.  Nurse 
Practitioners were just slightly more willing to provide MAT to OUD patients when surveyed 
post implementation.  Baseline and post implementation scores were both in the strongly agree 
range (4.6, 4.8 respectively). 
Theme 4: Perception 
The four statements pertaining to patient perception were 1, 8, 10, and 13.  Nurse 
Practitioners perceived slightly less resistance from their associates about the MAT program.  
Furthermore, NPs strongly agreed that the PCC supported the MAT program and the perception 
of organizational support did not change over the two months.  The NPs’ perception of having 
enough time with the patient increased from baseline.  Finally, the NPs believed that opioid 
addiction is a chronic disease, and there was only a minute increase in that belief. 
Statement 1 showed no major deviation from baseline.  Nurse Practitioners agreed that 
opioid addiction is a chronic disease at baseline and post implementation.  Nurse Practitioners 
may have agreed with the statement due to a different understanding of managing addiction.  
Instead of considering opioid addiction a transient disease, NPs may have considered a need for 
chronic disease management.   
Statement 8 showed no change from baseline.  Nurse Practitioners strongly agreed their 
organization supported their effort to treat OUD.  Organizational support was an important factor 
for NPs to feel that their work was valued and validated.  Lack of organization support was a 
frequently cited barrier to prescribing MAT for OUD (Jones, Campopiano, Baldwin, & 
McCance-Katz, 2015).  Multiple stakeholders with diverse responsibilities were affiliated with 
the project, indicating strong organizational support.  
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Nurse Practitioners indicated that they experienced more resistance from associates or 
place of work to continue/start MAT for opioid addiction (Statement 10).  However, the post-
implementation response remained in the strongly disagree to disagree category on the Likert 
Scale.  The result may have been influenced by one fewer NP responding to the statement, but 
NPs seem to have perceived support from their associates to continue/start MAT.   
Lastly, an improvement was seen in the NPs’ perception of having enough time to 
address addiction treatment needs (Statement 13). However, the mean response was still in the 
disagree range.  Appointment times varied from 20 to 40-minutes.  The treatment consent forms 
were lengthy and took the patient a large portion of the office visit to complete.  A shorter office 
visit meant the NP had less time for a thorough review of the patient’s medical, surgical, and 
social history, including past and present illicit drug use.  Often, the time for the NP to discuss 
treatment, provide education, and plan follow-up was insufficient. 
Impression 
Responses to the statements indicate an improved confidence in finding community 
resources for addiction, pathophysiology of opioid abuse, identifying opioid abuse among 
patients, and identifying additional MAT providers.  Each listed area was an often-cited barrier 
to providing MAT, which may have indicated NPs’ confidence in utilizing MAT for OUD 
improved following project implementation. 
Objective Four: Qualitative Provider Questionnaire 
The purpose of the questionnaire was to gather NP feedback about the BUP/NX MAT 
program.  Nurse Practitioner responses were reported in random order and displayed in Table 2. 
The NPs consider providing a service to patients in the community a program strength as 
the PCC treats patients regardless of their insurance or ability to pay.  Less disruption of patients’ 
 42 
lives during treatment and the support and collaboration with other providers were also 
considered a strength.  Lastly, support from providers, clinic staff, and the CDRC, which was 
considered a strength of the program, was notable since organizational support and additional 
prescribing providers are factors influencing willingness to prescribe MAT (Andrilla, Coulthard, 
& Larson, 2017). 
When asked, “What are the weaknesses of the program?” the responses centered on the 
need for additional services at the clinic and the barriers for program growth when affiliated with 
just one facility (CDRC).  The specific weaknesses listed included the lack of onsite counselors, 
delays in drug test results, and NP inexperience.  The PCC and CDRC do not share the same 
electronic medical record (EMR) system, which impeded retrieving rapid results from drug 
testing.  The testing policy stated that if a positive test result happened, the sample must be sent 
to another facility for confirmation because false positive results could occur.  The PCC and 
CDRC may agree to utilize the same EMR or the CDRC may fax lab results to the PCC prior to 
patient visits.  The PCC and CDRC both offer options for urine drug testing, so communication 
between providers at the PCC and staff at the CDRC may provide the necessary collaboration to 
establish the most efficient method of testing.  
Two NPs managed the maximum allotment of OUD patients, while other NPs may not 
have managed a patient in the first 2 months of the program.  Additionally, there were patients 
that left the program.  Nurse Practitioners disagreed about an acceptable patient load.  The NPs 
who treated the maximum number of OUD patients felt they could treat a larger number of 
patients, while the NPs who treated few or no OUD patients suggested the desire for a lower 
patient load.  Such findings may have indicated more experience working with OUD patients 
could lead to more NP comfort in treating the patient population.  Adjusting the exclusion 
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criteria for MAT to include patients with comorbid addictions, such as methamphetamine, may 
increase the number of available OUD patients.    
Nurse Practitioners also expressed a need for in-house counselors and case-managers 
with whom to collaborate.  The availability of addiction counselors within the PCC may assist 
with communication and ease of consult when treating complicated OUD patients.  However, 
such a request was outside the scope of this project, as it would require the PCC to expand 
payroll and create a position for hire.   
Although some NPs felt communication gaps between the CDRC and PCC existed, NPs 
also felt supported by fellow clinicians, staff members, and CDRC staff.  Since lack of 
institutional support was an often-cited barrier to prescribing MAT for OUD, such a sentiment 
was a positive finding (Hutchison et al, 2014).  The length and the understandability of the 
consent for treatment forms were concerning (Question 8).  During the initial evaluation, staff 
felt patients did not read or understand the consent forms in its entirety due to the length and 
withdrawal experience.    
Limitations 
Generalizability of the data from the surveys outside of the PCC was limited due to the 
small provider sample size.  However, the survey results may be generalized to the NPs within 
the confines of the PCC.  The limited number of participants completing the survey might also 
make NPs cautious when answering the qualitative questions for concern of being recognized.   
Under the buprenorphine prescriptive waiver, the NP can see up to 30 patients the first 
year and then apply for a waiver to treat up to 100 patients the ensuing year (American Society 
of Addiction Medicine, 2018).  During the pilot program, no NP managed more than five OUD 
patients at a given time.  As such, the opportunity for induction and follow-up care was limited.  
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Team members agreed that each NP could treat a maximum of five OUD at a given time during 
the program.  Some NPs did not obtain the maximum patient volume.  Lack of opportunity to 
treat OUD patients may have negatively affected NP confidence in their ability to provide MAT 
to this patient population.   
Further limitations of the pilot program involved the length of time between project start 
date and evaluation of NP confidence and distribution of questionnaires.  An interval of six 
months would allow an opportunity for NPs to manage a greater number of OUD patients.  
Surveys collected at longer intervals would also track progression of responses.  With a larger 
sample of providers, researchers could have looked for a correlation between the effect of 
provider experience and provider confidence prescribing MAT.  Lastly, inclusion of patients to 
gauge their impression of the project may have assisted in identifying strengths and weaknesses 
from a different perspective.  However, the purpose of the project was to assist in the creation of 
a pilot program to use MAT for OUD in the primary care setting and not specifically improving 
confidence or identifying NPs’ opinions of the project.  To this end, the project was successful.  
Recommendations 
Recommendations for future studies constitute the “Act” section of the PDSA.  Based on 
the data collected, including confidence surveys and interview questions, the project met the 
intended objectives.  My recommendations are to: 
• Encourage NPs at the PCC to continue treating OUD patients with BUP/NX.   
• Encourage fellow providers, who did not take part in the pilot program, to consider 
the training to obtain a buprenorphine prescription waiver.    
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• Allow primary care providers, such as NPs, to make the diagnosis of OUD based on 
the DSM-V criteria instead of professionals at the CDRC solely making the 
diagnosis.   
• Include the registered nursing staff in conducting COWS scoring.  Although the 
provider may collect a baseline assessment of opiate withdrawal, nurses can use the 
tool for subsequent evaluations during the induction period to maximize efficiency.   
• Discuss organizational roles.  Understanding roles would be important for other 
clinics who may be considering adopting a similar model.  The PCC and CDRC 
mutually benefitted from the alliance.  Each of the organizations lacked at least one 
element of care that the other could offer.  The patients benefited by the 
organizations’ comprehensive and holistic treatment approach. 
• Maximize visit appointment time by having patients read the consent for treatment 
forms prior to their visit with the primary care provider.   
• Assess patient materials for health literacy level and readability with tools like the 
CDC clear communication index, Flesch Reading Ease test, and the Flesch-Kincaid 
Grade Level Test.  All forms that are written at higher than a sixth-grade level should 
be revised to the lower literacy level.   
• Increase appointment times for new OUD patient referrals to 40 and 60 minutes to 
accommodate discussion of the consent form, education regarding the medication and 
program, and to collect a thorough past medical, surgical, and social history.  
• Allow more time to thoroughly describe the COWS tool as well as give examples of 
its use through case studies.  Have nurses perform a return demonstration or observe 
nurses COWS use with a patient.  
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• Expand the length of time between project start date and evaluation of NP confidence 
and qualitative interview to six months with the confidence surveys collected at 
baseline, three months and six months.  An interval of six months would allow NPs 
an opportunity to manage a greater number of OUD patients.  In future projects, 
consider tracking quality measures, attrition and completion rates as a measure of 
patient and provider outcomes.   
• Expand treatment to patients with multiple addictions as the referrals from the CDRC 
were limited to approximately 10 patients divided between five NPs. 
• Determine the optimal patient load for the PCC providers going forward, one that 
may allow additional chances to provide MAT to OUD patients. 
• Consider forming an alliance with more addiction treatment organizations to increase 
patient volume and allow NPs more opportunity to treat OUD patients. 
• Form a lobby of providers and staff from the PCC and CDRC.  The purpose of the 
lobby would be to advocate for improving access to MAT for OUD at the city 
government and state government levels. 
• Schedule project follow-up meetings for all stakeholders every six months and as 
needed.  The PCC and CDRC team should share the responsibility in determining the 
future direction of the program. 
Dissemination 
Dissemination of project and results may assist in improving NP practice and encourage 
expansion of current primary care provider roles.  The plan for dissemination includes a poster 
presentation at NDSU Memorial Union on April 9, 2019 and submission for publication.  
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Targeted journals for publication include peer-reviewed journals in advanced nursing practice, 
substance abuse and treatment, interprofessional practice or practice management.   
Implications for Future Research 
The desired outcome of the project was to assist in creating a BUP/NX MAT program 
that is not only high quality and evidence based, but also one that meets the needs of the 
providers, patients, and community.  The project is unique in that the two organizations (PCC 
and CDRC) collaborated to serve the needs of the community as well as each organization.  
Future research may focus on patient outcomes, patient satisfaction, and provider satisfaction of 
collaborative programs compared to independent programs.  The opioid epidemic is a priority of 
many national, state, and local agencies (U.S. Drug Enforcement Agency, 2016).  With the 
limited patient access to addiction programs, primary care may be an ideal option for BUP/NX 
MAT.  Applying a theoretical framework such as the SEM may also help address the 
multilayered influences that determine behavior and create an environment conducive to change 
through collaboration with additional community organizations.  Finally, the pilot program 
implemented at the PCC provided a blueprint for other clinics to develop a similar primary care 
model to address opioid dependence.  
Application to the Nurse Practitioner Role 
Nurse Practitioners are well-educated health care providers who manage acute and 
chronic illnesses.  As more opioid addicted patients seek treatment, the NP must be 
knowledgeable and prepared to meet the challenge.  Through Section 303 of the CARA, NPs 
may receive training and utilize their knowledge and skill to manage OUD in the primary care 
setting (SAMHSA, 2018).  The results of the confidence survey may help to ease concerns of 
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NPs about prescribing BUP/NX for OUD.  The blueprint from this pilot project may also be 
beneficial to other clinics considering starting a MAT for OUD program.   
Primary care opioid addiction therapy has been underutilized while more traditional 
MAT, such as methadone, has several barriers influencing compliance and satisfaction with the 
therapy (Jenkin & Ravert, 2013; Hill et al., 2015).  The primary care setting offers an opportunity 
to manage OUD as a chronic illness using BUP/NX MAT.  Several barriers limit the number of 
primary care providers being willing to prescribe MAT for OUD (Andrilla, Coulthard, & Larson, 
2017).  However, obtaining the training needed to become knowledgeable and confident 
providers would allow NPs the opportunity to fill the gaps in the management of OUD. 
Nurse Practitioners may further help to reduce the stigmatization of OUD by being 
supportive and not passing judgement during patient interactions (Cadet & Tucker, 2019).  
Treatment programs rooted in primary care settings may offer a convenient and therapeutic 
environment for patient sobriety and relapse prevention while experiencing more respect, trust, 
and empathy from providers (Jenkinson and Ravert 2013).  Taking a patient-centered approach 
to care, including shared decision making between providers and patients, may help patient 
retention, prevent relapses, and overcome barriers to seeking MAT for OUD (Cadet & Tucker, 
2019). 
Conclusion 
Opioid addiction is an epidemic affecting every state in the nation (Kaiser Family 
Foundation, 2018).  MAT, combined with counseling, can successfully treat OUD, help sustain 
recovery, and decrease risk behaviors by providing individualized approach to opioid addiction 
therapy (SAMHSA, 2016).  However, significant gaps between treatment need and capacity exist 
at the state and national level (Jones, Campopiano, Baldwin, & McCance-Katz, 2015).  Offering 
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MAT through the primary care setting may increase the availability of treatment options for 
OUD patients.  Additionally, NPs offer an opportunity to address gaps in patient access to high 
quality, patient-centered, and affordable health care (IOM, 2011) including MAT for OUD 
through Section 303 of the CARA (SAMHSA, 2018).  Utilization of an interdisciplinary model 
to address the multilayered and collaborative effects of personal and environmental influences of 
OUD may help to provide an individualized and structured approach to treatment.  
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APPENDIX A. CLINICAL OPIATE WITHDRAWAL SCALE (COWS) 
For buprenorphine/naloxone induction: Enter scores at time zero, 1-2 hours after 
first dose, and at additional times buprenorphine/naloxone is given over the 
induction period. 
DATE/TIME DATE/TIME DATE/TIME 
Resting Pulse Rate: (record beats per minute) Measured after patient is 
sitting/lying for one minute.  
0 = 80 or below; 1 = 81-100 ; 2 =101-120; 4 => 120  
   
Sweating: Over past ½ hour not accounted for by room temperature or patient 
activity. 
 0 no report of chills or flushing 1 one report of chills or flushing; 2 flushed or 
observable moistness on face 3 beads of sweat on brow or face 4 sweat streaming 
off face  
   
Restlessness: Observation during assessment.  
0 able to sit still; 1 reports difficulty sitting still, but is able to do so; 3 frequent 
shifting or extraneous movements of legs/arms; 5 unable to sit still for more than 
a few seconds  
   
Pupil Size: Observation during assessment.  
0 pupils pinned or normal size for room light; 1 pupils possibly larger than normal 
for room light; 2 pupils moderately dilated; 5 pupils so dilated that only rim of the 
iris is visible  
   
Bone or Joint aches: If patient was having pains previously, only the additional 
component attributed to opiate withdrawal is scored.  
0 not present; 1 mild diffuse discomfort; 2 patient reports severe diffuse aching of 
joints/muscles   4 patient is rubbing joints or muscles and is unable to sit still 
because of discomfort  
   
Runny nose or tearing: Not accounted for by cold symptoms or allergies.  
0 not present; 1 nasal stuffiness or unusually moist eyes; 2 nose running or 
tearing; 4 nose constantly running or tears streaming down cheeks  
   
GI Upset: Over last ½ hour.  
0 no GI symptoms; 1 stomach cramps; 2 nausea or loose stools; 3 vomiting or 
diarrhea; 5 multiple episodes of diarrhea or vomiting  
   
Tremor: Observation of outstretched hands.  
0 no tremor; 1 tremor can be felt, but not observed; 2 slight tremor observable;    
4 gross tremor or muscle twitching  
   
Yawning: Observation during assessment.  
0 no yawning 1; yawning once or twice during assessment; 2 yawning three or 
more times during assessment; 4 yawning several times/minute  
   
Anxiety or Irritability:  
0 none; 1 patient reports increasing irritability or anxiousness; 2 patient obviously 
irritable, anxious; 4 patient so irritable or anxious that participation in the 
assessment is difficult  
   
Gooseflesh skin:  
0 skin is smooth; 3 piloerection of skin can be felt or hairs standing up on arms;     
5 prominent piloerection  
   
Total Score     
Observer’s Initials     
Blood Pressure/Pulse     
Dose of Suboxone® Given     
 
SCORE: Mild: 5-12; Moderate: 13-24; Moderately Severe: 25-36; Severe Withdrawal: More than 36. 
 
Adapted from DEPARTMENT OF VERMONT HEALTH ACCESS MANAGED CARE ENTITY VERMONT BUPRENORPHINE PRACTICE 
GUIDELINES Revised 08/2015 
http://dvha.vermont.gov/for-providers/buprenorphine-practice-guidelines-revised-final-10-15.pdf   
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APPENDIX B. CONSENT FOR TREATMENT WITH BUPRENORPHINE/NALOXONE 
COMBINATION THERAPY MEDICATION 
Buprenorphine and naloxone are medications approved by the Food and Drug Administration 
(FDA) for treatment of people with opioid dependence. Qualified providers can treat patients for 
opiate dependence.  Buprenorphine can be used for detoxification or for maintenance therapy.  
Maintenance therapy can be used as long as medically necessary. Buprenorphine/Naloxone is 
one treatment option for opiate addiction and other options such as methadone, naltrexone, and 
counseling may be used if Buprenorphine/Naloxone is ineffective. Counseling is the only other 
form of treatment that may be used in combination with Buprenorphine/Naloxone. 
Buprenorphine/Naloxone should not be used with other medications specifically indicated for 
opiate addiction.  
 
Buprenorphine itself is an opioid, although it affects the brain differently than other opiates. It is 
not as strong an opioid as heroin or morphine. Buprenorphine, when used as a medication-
assisted treatment for opiate addiction (M.A.T.), suppresses withdrawal symptoms, cravings for 
opiates, does not cause euphoria (the feeling of being “high”) in opiate dependent patients, and 
blocks the effects of other opiates for at least 24 hours-48 hours.  Buprenorphine treatment can 
still result in physical dependence of the opiate type.  
 
If you are dependent on opiates, you should be in active, moderate withdrawal when you take the 
first dose of buprenorphine. The more withdrawal you are able to be in for the induction process, 
the better we will be able to determine a good dose of medication for you to be on. If you are not 
in withdrawal, buprenorphine may cause significant opioid withdrawal since it blocks the effects 
that other opiates have in your body. For that reason, you should take the first dose in the office 
and remain in the office for observation.   
 
Buprenorphine/Naloxone films/tablets must be held under the tongue until it is dissolved 
completely. Do NOT swallow the film/tablet. The medication is not absorbed well in the 
stomach. If the medication is swallowed, you will not receive the full benefit of the medication 
and it may not resolve your withdrawal symptoms. Allow the medication to dissolve fully under 
your tongue. This may take up to 10 minutes. The medication is then absorbed over the next 30 
to 120 minutes from the tissue under the tongue.  
 
Some patients find that it takes several days to get used to the transition from the opioid they had 
been using to buprenorphine. During that time, any use of other opioids may cause an increase in 
symptoms. After you become stabilized on buprenorphine, it is expected that other opioids will 
have less effect. Attempts to override the buprenorphine by taking more opioids could result in 
an opioid overdose. You should not take any other medication without discussing it with your 
medical provider first. 
 
Combining buprenorphine with alcohol and/or certain medications may be hazardous. The 
combination of buprenorphine with alcohol and/or benzodiazepines (such as Valium, Librium, 
Ativan, Xanax, Klonopin, etc.) has resulted in deaths. If a benzodiazepine is prescribed,  
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It must be taken only as prescribed and with approval from your Buprenorphine/Naloxone 
prescriber and any specialist providers.  
 
Buprenorphine/Naloxone is extremely dangerous for infants and children. They can stop 
breathing and die quickly after taking in tiny amounts of this medication. This is why it is very 
important to keep medication locked/secured at all times and out of the reach of children at all 
times. 911 should be called immediately if there is any chance an infant/child may have 
ingested buprenorphine/naloxone.  
 
I have read and reviewed this information with my medical provider and I understand how 
Buprenorphine/Naloxone treatment is utilized to treat an opioid use disorder. I understand the 
risks and benefits of this treatment. I have an opportunity to discuss my questions with my 
provider and I consent to proceeding with Medicated Assisted Treatment. 
 
 
___________________________________ 
Patient Signature 
 
___________________________________ 
Patient’s Printed Name 
 
_____________ 
Date 
  
 60 
APPENDIX C. BUPRENORPHINE/NALOXONE TREATMENT CONTRACT 
As a participant in buprenorphine/naloxone treatment for opioid use disorder, I agree to the 
following by reviewing and initialing each statement and signing this treatment contract: 
 
• I agree to keep all my scheduled appointments or change the appointment in advance, 
except in case of emergency.  __________ 
• I agree that my prescriptions for Buprenorphine/Naloxone will only be given to me at my 
office visits. A missed visit will result in my not being able to get my 
medication/prescription until the next scheduled visit. _________ 
• I agree to use a single pharmacy for all of my prescription medications_________ My 
chosen pharmacy is.____________________. I will not transfer my prescription to other 
pharmacies or fill at multiple pharmacies. _______. If I choose to switch pharmacies, I 
may do so one time and will notify ___________ nursing staff.___________ 
• I agree to obtain my prescriptions for Buprenorphine/Naloxone only from my provider 
____________________ at ___________. I will notify any other health care provider and 
dentist that I am on buprenorphine/naloxone therapy and will not seek additional 
controlled substances from other providers. __________ 
• I agree to report an accurate health history and symptoms to the health care team 
involved in my care. I will also inform my provider prior to any dental surgery or other 
surgical procedures. ___________ 
• I understand/agree that if I have a mental health disorder in addition to my opioid use 
disorder, it is important that I am following my treatment plan with my behavioral health 
provider and that ___________ has access to those records. It is also important that my 
behavioral health provider has access to my ___________ records. ________ 
• I agree to take my Buprenorphine/Naloxone as prescribed, not to skip doses, and not to 
adjust the dose unless discussed with my provider first. ___________ 
• I agree NOT to sell, share, or give any of my medication to another person. Also, I 
agree not to buy or sell used film wrappers.  __________ 
• I agree not to deal, buy, or use any drugs at _____________, in its parking lots or 
property. Additionally, I agree to not engage in any illegal activity at ___________. 
_________ 
• I agree to provide up to date contact information and have a reliable phone number where 
I can be reached. My phone will be charged at all times. I will have minutes on my 
phone. I will always have my phone in my possession. I will have a voicemail box set up 
on my phone and make sure there is available space for nursing to leave a voicemail. I 
will return nursing’s phone call within 24 hours.  ___________ 
o My primary phone numbers are. ______________________ and 
__________________ 
• I agree that if I am going to be unreachable for any reason, I must discuss this with ____ 
nursing staff beforehand and explain the situation._______________ 
• I agree that if I am planning an out of town trip, I agree to provide 2 weeks (14 day) 
notice to ____ nursing staff to discuss any potential treatment adjustments. 
_______________________ 
• I agree that the medication I receive is my responsibility and I agree to keep it safe and 
secure and locked up. I agree that lost/ stolen prescriptions and medication will not be 
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replaced regardless of why it was lost/ stolen. Also, Lost/stolen prescriptions must be 
reported to the police and a police report must be provided at the next visit. I understand 
that if my medications are lost/stolen, my provider is not expected to provide “make-up” 
doses.  __________ 
• I agree to avoid driving or operating heavy machinery/dangerous equipment until I am 
familiar with the effects of the buprenorphine/naloxone.__________ 
• I agree not to obtain buprenorphine (Suboxone, Zubsolv,), other opioids (such as 
morphine, fentanyl, hydrocodone, oxycodone, or tramadol), benzodiazepines (for 
example, Lorazepam, Diazepam/Valium, Clonazepam/Klonopin, Alprazolam/Xanax, 
etc.), Gabapentin, or Lyrica from any other healthcare providers, pharmacies, or other 
sources without telling my ____ provider. __________ 
• I understand that mixing buprenorphine with other medications, especially 
benzodiazepines, can be dangerous and could lead to death. There is also a risk of 
overdose death from mixing buprenorphine (Suboxone) with alcohol or other types of 
sedatives, such as barbiturates. _________ 
• I agree to inform all of my professional providers about any of the following: 
o Use of medication in any other way that prescribed._________ 
o Use of other opioids, alcohol, illicit benzodiazepines, or other illicit 
drugs._________ 
• I understand that Buprenorphine/Naloxone by itself may not be enough treatment for my 
addiction, and I agree to participate in counseling/support groups as discussed and agreed 
upon with my healthcare provider. I agree to follow all recommendations for counseling 
and psychiatric services and make all records from outside providers available to my 
____ provider. _______ 
• I understand and agree that the ___________ nursing staff or my ___________ provider 
may request phone updates or records from my addicting counseling staff at any time 
regarding my progress and attendance of treatment/therapy sessions. Also, I understand 
that my treatment provider may request verbal updates and records from ___________  at 
any time.__________ 
• I agree to treat staff with respect and not to disturb other patients or threaten, verbally 
abuse, or in any manner accost staff members or patients while on or around clinic 
property. _________ 
• I will not use any nicotine-containing products in/around clinic property. __________ 
• I agree to provide random urine samples for drug testing and have my healthcare provider 
test my blood alcohol level whenever I am asked to do so. I understand that failure to 
provide a urine sample within 24 hours of when requested could result in involuntary 
tapering of Buprenorphine/Naloxone and discontinuation of treatment.__________ 
• I agree to be 20 minutes early for my appointments. I understand that if I am late 10 
minutes or more that I may be asked to reschedule my appointment and will not get my 
prescription that day. I agree that I will arrange my own reliable transportation in advance 
and make it to my appointments in a timely fashion. ____________ 
• If I am female, I confirm that I am not pregnant.  I agree to prevent pregnancy and use 
reliable birth control while using buprenorphine containing products. I agree to inform 
my provider if I become pregnant as other treatment options may be discussed. I 
understand that my provider has the ability to prescribe birth control if needed and that 
condoms are free to me at ___________. _________ 
 62 
• If I contract Hepatitis I will let my medical provider know as my liver function may need 
to be monitored more closely.________ 
• I agree to keep all unused doses of medication, medication film wrappers, and the 
original containers from the pharmacy and bring them to each appointment to be 
inspected and counted.________  
• I understand that my provider may also require random film counts. If I am called to 
come in for a random film count, I will present to ___________ within 24 hours of being 
called. I will present with all remaining films and wrappers from used films since last 
prescription was provided. _______ 
• I agree that my goal is to stop using addictive drugs, and that I will work to stop using all 
addictive and illegal drugs during my treatment with Buprenorphine/Naloxone. _______ 
• I understand that if I decrease my use of opioids (stop using heroin, pain pills) or 
substitute buprenorphine for these drugs, I have a higher risk of dying from an overdose 
if I relapse as my body is no longer used to the higher doses of opioids that I was 
previously using. _________ 
• I understand that if I relapse when I have been taking buprenorphine, at first I may not get 
high from the other opioids because buprenorphine blocks their effect. I understand that if 
I keep using larger and larger amounts to try to get high, I could stop breathing and die. 
_______ 
• I understand that Buprenorphine/Naloxone is extremely dangerous for infants and 
children. They can stop breathing and die quickly after taking in tiny amounts of 
this medication. I agree to keep my supply of this medication locked securely away from 
others, especially infants and children. I agree to call 9-1-1 immediately if anyone other 
than myself has been in contact with my medication and inform my medical 
provider.________ 
• I understand that relapse is sometimes part of the recovery process. I agree to discuss any 
concerns or relapses with my provider to discuss ways to prevent future occurrences. If I 
feel like I may relapse, I will contact my provider immediately ________ 
• I agree to not eat any foods or bakery items that contain poppy seeds, including 
“everything” bagels or use any mouthwash or cough syrup containing alcohol. I 
understand that this will not be accepted as an excuse for a positive drug screen._______ 
• I agree to sign and have an active release of information on file to ___________ for all of 
my mental health records, hospitalizations/ER visits, addiction treatment 
providers/counselors, and any other medical services. I understand that revocation of any 
releases of information may result in dismissal from the buprenorphine/naloxone 
program.__________ 
• I understand that, like all health care providers, ___________ staff are mandated 
reporters of suspected abuse, neglect or exploitation of vulnerable groups of people 
including children and elderly adults. Healthcare providers and nurses are legally 
required to report any potential or suspected abuse/neglect of these 
populations.____________ 
• I understand that provider will regularly check the pharmacy controlled substance online 
database on a regular basis and any controlled substances (such as benzodiazepines, 
opioids, stimulants, gabapentin, Lyrica, sleep medication) prescribed and filled without 
my provider’s knowledge could result in dismissal from buprenorphine/naloxone 
treatment program_________ 
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• I understand that I will be considered to have left the buprenorphine/naloxone treatment 
program against medical advice if I am not able to be contacted within 3 days of a missed 
appointment._________ 
• I understand that if I leave the program against medical advice and wish to re-engage, I 
will need to be re-evaluated by an addiction counselor to see if buprenorphine/naloxone 
is an appropriate treatment for me and my counselor will need to be in touch with my 
___________ buprenorphine prescribing provider as to his/her recommendations. If I am 
re-accepted to the program I will have to re-start at a higher level of care._________ 
• I have reviewed the ___________ Medicated Assisted Treatment for Opioid Use 
Disorder and am agreeable to the plan of care. I understand that once I graduate from 
Stable Level Care, my provider and I may agree on a Maintenance Level of Care which 
can be individualized to me and my current progress with my disease. I understand that 
failure to maintain or progress at one level of care may require me to go back to a higher 
level of care.__________ 
• I agree that if I accrue any bills at ___________ I will work with the billing office to start 
a payment plan if I cannot afford my bill. I understand that if the balance of my bill 
reaches or exceeds $200 dollars without actively trying to make payments on my bill that 
I may not be able to go to my office visits and therefore will not get my prescription. 
_________ 
• I understand that failure to comply with this Treatment Contract, recommendations from 
my healthcare provider, or recommendations from my addiction counselor could carry 
implications to my current treatment plan such as (ranging from less severe to most 
severe);__________ 
o Transfer to a higher level of care within ___________ (for example, more 
frequent office visits, more frequent urine screenings, more frequent film counts, 
shorter prescriptions.) 
o Conferences with my care team regarding my progress and appropriateness for 
continuing medication assisted treatment. 
o Involuntary tapering of buprenorphine and dismissal from buprenorphine 
treatment program at ___________. 
o In severe cases if the safety of well-being of our staff/patients is in question, I 
may be discharged from ___________ and asked not to return for a specified 
amount of time. 
• I understand that my buprenorphine/naloxone treatment may be discontinued, I may be 
involuntarily tapered off my buprenorphine medication, and I may be discharged from 
the buprenorphine/naloxone program if the terms of this agreement are violated. 
__________ 
 
 
Patient signature_____________________________________________________________ 
 
Date_____________________ 
 
Provider name & signature________________________________________________ 
 
Date___________________ 
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APPENDIX D. BUPRENORPHINE/NALOXONE MEDICATION CALL BACK FOR 
FILM COUNTS AND REFILL INFORMATION 
• Medication Film Counts and Call-backs are an important aspect of treatment and a tool to 
help assure Buprenorphine/Naloxone (Suboxone) is taken as directed and is not being 
diverted (sold, shared, horded, etc.). If you do not return for a medication call-back or do 
not bring your films in for a film count, we must assume that you are engaged in one or 
more of these behaviors.___________ 
 
• You must save the container that you received your medication in, the film wrappers, and 
any films that you have not yet taken and they must be readily available to be counted 
and examined by nursing at any time_________ 
 
• It is your responsibility to have a working phone number for staff to be able to use. If you 
cannot be reached due to an outdated phone number, full voicemail, etc., then the call-
back is considered unsuccessful. It is your responsibility to check your voicemail each 
day and delete old messages to ensure room for new messages. ___________ 
 
• If you are called by nursing for a Call-Back and asked to come in for a film count, we 
expect that nursing is able to reach you by phone to notify you of the need to do this. 
There should be no more than 8 business hours lapse between the nursing calling you and 
you returning her call. Once the nurse has been in touch with you, you must present to the 
clinic with the unused portion of your medications still in the original wrappers, the 
empty wrappers, and whatever container you originally received the medication 
in.__________ 
 
• Be aware that due to the risk of diversion of buprenorphine containing products, nursing 
staff will be examining and counting the films left in the prescription, counting the 
number of used film wrappers from previously used doses, and comparing lot numbers.  
______________ 
 
• In addition to call-backs, it is expected that at each office visit you bring in any unused 
films in addition to the film wrappers. ___________ 
 
• It is your responsibility to have your medication and the film wrappers safely secured at 
all times (in a locked box preferably). Having your medication/film wrappers stolen or 
lost will not be considered a reasonable excuse in the event of the need for a call back. 
___________  
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Refills 
 
Medication will NOT be refilled on weekends, holidays, or after regular business hours. Refills 
will only be given in the office visit. Monitoring and being responsible for your medication is 
your responsibility and an important part of your recovery.  
 
Patient Signature: ___________________________________________________ 
 
Date: ____________________________________ 
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APPENDIX D. PROVIDER SURVEY 
Statement Strongly 
Disagree 
Disagree Undecided Agree Strongly 
Agree 
1. I view opioid addiction as a chronic 
disease.  
1 2 3 4 5 
2. I can identify resources in the 
community to aid in addiction therapy. 
1 2 3 4 5 
3. I can identify specialty services for 
complex comorbidities.  
1 2 3 4 5 
4. I feel knowledgeable regarding the 
pathophysiology of opioid abuse.  
1 2 3 4 5 
5. I am willing to provide medication 
assisted treatment (MAT) for opioid use 
disorder (OUD). 
1 2 3 4 5 
6. I am confident in my ability to identify 
opioid abuse among my patients. 
1 2 3 4 5 
7. I am confident in my ability to manage 
patients with MAT for opioid abuse. 
1 2 3 4 5 
8. The organization that I work for helps 
support my efforts to treat OUD.  
1 2 3 4 5 
9. I can identify fellow providers who 
provide MAT with buprenorphine/ 
naloxone for OUD.  
1 2 3 4 5 
10. I feel that there is resistance from my 
associates or place of work to continue/ 
start MAT for opioid addiction.  
1 2 3 4 5 
11. I am hesitant to prescribe 
buprenorphine/naloxone due to 
prescription misuse or diversion.    
1 2 3 4 5 
12. I am hesitant to prescribe 
buprenorphine /naloxone due to 
concerns about cost reimbursement. 
1 2 3 4 5 
13. I believe that I have enough time during 
office visits to address my patient’s 
addiction treatment.    
1 2 3 4 5 
14. I am comfortable talking about opioid 
abuse/addiction with my patients. 
1 2 3 4 5 
15. I would feel more confident in providing 
MAT for OUD if my patient is also 
receiving addiction counseling.  
1 2 3 4 5 
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APPENDIX F. PROVIDER INTERVIEW QUESTIONS: 
In regard to the Buprenorphine-Naloxone Medication Assisted Treatment Program: 
 
1. What do you perceive as the strengths of the program? 
 
 
 
2. What are the weaknesses of the program?  
 
 
 
3. What are your opinions about the referral process and relationship with CDRC employees?  
 
 
 
4. What have been the biggest barriers for providers and the clinic in first three months of the 
program? 
 
 
 
5. Do feel the evaluation process is comprehensive and meets the needs of providers, the clinic, 
and the patients? Explain your answer.  
 
 
 
6.  What is your current patient load and what do you believe is an acceptable patient load 
going forward? 
 
 
 
7. What factors have promoted patient retention in the program? 
 
 
 
8. Have you found the program forms or evaluation tools lack clarity? If so, how? 
 
 
 
9. What recommendations for improvement would you like to see made to the program? 
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APPENDIX G. MEDICATION ASSISTED TREATMENT PROVIDER ORDER SET 
 Referral to CDRC  
 CDRC Collected and Observed UDS Standing Order 
 CDRC Collected and Observed Urine Drug Screen  
 Comprehensive Metabolic Panel  
 Hepatitis C Ab with reflex to hepatitis C PCR 
 Hepatitis B surface antigen  
 Hepatitis B surface antibody 
 HIV 1 Ag HIV ½ Ab with reflex to confirmation  
 Hepatic panel 
 Urine, HCG.   
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APPENDIX H. POWERPOINT PRESENTATION 
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APPENDIX I. NDSU IRB APPROVAL 
 
NDSU is an EO / AA  universit y.
INSTITUTIONAL REVIEW  BOARD
NDSU Dep t  40 0 0   |  PO Bo x 60 50   |  Fargo ND 5810 8-60 50   |  7 0 1.231.8995  |  F ax 70 1.231.80 98  |  ndsu.edu/ irb
Shipping  addr ess: Research 1, 1735 NDSU Research Park Drive, Fargo ND 5810 2
November 14, 2018        
 
Dr. Tina Lundeen 
Nursing 
 
Re:       IRB Determination of Exempt Human Subjects Research:  
Protocol #PH19088,  “Development and Implementation of an Evidence-Based Buprenorphine-Naloxone 
Medication Assisted Treatment Program in a Primary Care Setting” 
              
Co-investigator(s) and research team: Jordan Coplin 
Date of Exempt Determination:  11/14/2018  Expiration Date: 11/13/2021 
Study site(s): Family HealthCare 
Sponsor: n/a 
 
The above referenced human subjects research project has been determined exempt (category #2b) in accordance 
with federal regulations (Code of Federal Regulations, Title 45, Part 46, Protection of Human Subjects).  This 
determination is based on the protocol submission (received 11/7/2018) with updated information sheet (received 
11/14/18).   
 
Please also note the following: 
• If you wish to continue the research after the expiration, submit a request for recertification several weeks prior 
to the expiration.  
• The study must be conducted as described in the approved protocol.  Changes to this protocol must be approved 
prior to initiating, unless the changes are necessary to eliminate an immediate hazard to subjects.   
• Notify the IRB promptly of any adverse events, complaints, or unanticipated problems involving risks to 
subjects or others related to this project. 
• Report any significant new findings that may affect the risks and benefits to the participants and the IRB. 
 
Research records may be subject to a random or directed audit at any time to verify compliance with IRB 
standard operating procedures. 
 
Thank you for your cooperation with NDSU IRB procedures.  Best wishes for a successful study. 
Sincerely, 
 
 
 
Kristy Shirley, CIP, Research Compliance Administrator  
 
For more information regarding IRB Office submissions and guidelines, please consult 
http://www.ndsu.edu/research/integrity_compliance/irb/. This Institution has an approved FederalWide 
Assurance with the Department of Health and Human Services: FWA00002439. 
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APPENDIX J. EXECUTIVE SUMMARY 
Project Summary 
The purpose of this project was to assist a primary care clinic (PCC) in Fargo, ND with 
the development, implementation, and evaluation of a buprenorphine-naloxone medication 
assisted treatment (MAT) option for opioid use disorder (OUD) patients in collaboration with a 
chemical dependency residential center (CDRC).  Opioid abuse is one of the most significant 
drug-related public health threats in the United States (U.S. Drug Enforcement Agency, 2016).  
Approximately 115 Americans die every day from an opioid overdose in the United States 
(Center for Disease Control and Prevention, 2017).  North Dakota had one of the fewest opioid 
related death rates in the country with 54 opioid-related overdose deaths in 2016.  However, this 
was an increase from 34 deaths the year prior and from the 11 opioid related deaths in 2013 
(Kaiser Family Foundation, 2018).  
Coupled with counseling, MAT can successfully treat opioid use disorder and sustain 
recovery by providing a more individualized approach to therapy (Substance Abuse and Mental 
Health Services Administration (SAMHSA), 2016).  Methadone had historically been used to 
treat opioid addiction in the U.S. but can only be prescribed in treatment programs certified by 
SAMHSA.  The availability of and access to certified treatment centers have not met the 
increasing need for MAT services created by the prescription drug dependence epidemic 
(Jenkins & Ravert, 2013).  Opportunities within the primary care setting exist to manage OUD 
with buprenorphine-naloxone.  
Background 
The project was a new concept in the treatment of OUD in the Fargo-Moorhead 
community.  Traditional methods to treat OUD, such as methadone clinics, as well as private 
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treatment programs were available.  However, no outpatient clinic in the Fargo, ND community 
had developed a primary care model utilizing BUP/NX for outpatient OUD treatment.  Members 
from a PCC and CDRC joined forces to provide a comprehensive treatment program for OUD.  
The objective was to deliver high quality, focused care to a larger number of patients 
participating in the MAT program.  Nurse practitioners could obtain a waiver to prescribe 
buprenorphine for up to 30 patients (in year one) through SAMHSA after 24 hours of training (8 
hours of which is specific to safe medication prescribing) (American Society of Addiction 
Medicine, 2018).  Patients received addiction counseling and case management services at the 
CDRC while NPs at the PCC provided medication assistance 
Between March 2018 and May 2018, discussion of an evidence-based BUP/NX program 
was discussed between members of the PCC.  Determination of needs was established by PCC 
providers and staff.  Networking with additional community organizations including the CDRC 
began May 2018 through September 2018.  The initial literature review of BUP/NX use in 
primary care was completed between June 2018 and October 2018.  Networking with CDRC 
representatives and PCC representatives to discuss necessary forms and other project needs 
occurred September 2018.  Providers at the PCC completed the mandatory 24-hour training to 
receive a buprenorphine prescription waiver through the Department of Vermont Health Access 
in Vermont between June 2018 and September 2018. 
Stakeholders in the project included representatives from the CDRC such as counselors, 
case managers, the clinical director, and the CEO.  Shareholders from the PCC included the 
medical director, nurse practitioners, nurses, appointment schedulers, pharmacists, and financial 
enrollment staff. 
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Process 
Five NPs completed the required 24-hours of training to receive a buprenorphine 
prescriptive waiver prior to the project start date.  Additional training in utilizing the COWS was 
completed by nurses at the PCC during a brief, 10-minute in-service discussion on February 4, 
2019.  BUP/NX MAT guidelines, consent for treatment, and a provider order-set were 
distributed on August 22, 2019 to the medical director and NPs who had completed the required 
BUP/NX training.  The clinical service manager and a nurse at the PCC edited the consent forms 
and order-set to better reflect the needs of the PCC, which were approved on September 24, 2019 
by the PCC stakeholders.  Due to the timeline needs of the PCC, the forms were completed prior 
to the project start date.  The initial provider confidence surveys were distributed on November 
16, 2018 to NPs at three clinic locations in Fargo, ND and West Fargo, ND.  Post-
implementation confidence surveys were distributed on January 28, 2019 during a MAT provider 
meeting at the PCC.  Additionally, qualitative, open-ended questionnaires were dispersed at the 
same time as the post-implementation confidence surveys. 
Evaluation of NP confidence consisted of provider confidence surveys administered at 
the start of project implementation and two months post-implementation.  A 5-point Likert scale 
reflecting the response categories of strongly agree, agree, undecided, disagree, strongly disagree 
was used.  The survey consisted of 15 statements created to evaluate the various determinants 
that affect provider confidence in MAT.  Statements also evaluated common barriers associated 
with providing MAT for OUD.  The response rate was 100% at baseline and 80% post-
implementation with one statement not responded to by one provider.  
The questionnaire consisted of nine open-ended questions designed to elucidate the 
perceived strengths and weaknesses of the project.  Four NPs completed the questionnaire 
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(response rate of 80%).  Responses were randomized to decrease the possibility of identifying 
the respondent.  The statements within the survey and questions within the questionnaire were 
original and did not come from a previously utilized survey. 
Findings and Conclusions  
The NPs used the guidelines, consent form and treatment agreement form, and the 
provider order-set during the MAT project starting November 16, 2018.  Following the in-
service presentation, the PCC nurses expressed an interest in using COWS, however, they were 
concerned about using the tool in the clinical setting without additional training. The analysis at 
the conclusion of this project also included the overall results of the pre and posts 
implementation Likert Scale surveys and qualitative questionnaires.  The statements on the 
provider survey were organized into four themes, which include confidence or lack of 
confidence, knowledge, willingness, and perception.  Responses to the statements indicate an 
improved confidence in finding community resources for addiction, understanding the 
pathophysiology of opioid abuse, identifying opioid abuse among patients, identifying additional 
MAT providers, and willingness to provide MAT.  Each listed area was an often-cited barrier to 
providing MAT, which may have indicated NPs’ confidence in utilizing MAT for OUD 
improved following project implementation.  Results are as follows:   
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Table J1 
   
Provider Confidence Survey 
   
Statements 
Baseline 
N=5 
Post 
N=4 
Diff 
6. I view opioid addiction as a chronic disease.   4.2 4.3 0.1 
7. I can identify resources in the community to aid in addiction therapy. 4.0 4.5 0.5 
8. I can identify specialty services for complex comorbidities.  4.0 4.3 0.3 
9. I feel knowledgeable regarding the pathophysiology of opioid abuse.  3.8 4.5 0.7 
10. I am willing to provide medication assisted treatment (MAT) for opioid 
use disorder (OUD). 
4.6 4.8 0.2 
16. I am confident in my ability to identify opioid abuse among my patients. 3.8 4.3 0.5 
17. I am confident in my ability to manage patients with MAT for opioid 
abuse.  
3.4 3.8 0.4 
18. The organization that I work for helps support my efforts to treat OUD.  4.8 4.8 0.0 
19. I can identify fellow providers who provide MAT with 
buprenorphine/naloxone for OUD.  
4.2 4.8 0.6 
20. I feel that there is resistance from my associates or place of work to 
continue/start MAT for opioid addiction.  
1.2 1.8 0.6 
21. I am hesitant to prescribe buprenorphine/naloxone due to prescription 
misuse or diversion.    
2.8 2.5 -0.3 
22. I am hesitant to prescribe buprenorphine/naloxone due to concerns about 
cost reimbursement. 
1.6 1.5 -0.1 
23. I believe that I have enough time during office visits to address my 
patient’s addiction treatment.    
2.4 2.8 0.4 
24. I am comfortable talking about opioid abuse/addiction with my patients. 4.4 4.5 0.1 
25. I would feel more confident in providing MAT for OUD if my patient is 
also receiving addiction counseling.  
4.8 4.8 0.0 
 
Through analysis of the qualitative questionnaire, nurse practitioners indicated positive 
feelings about the program and the working relationship within the PCC and with the CDRC 
providing a service to underserved patients in the community, and less disruption of patients’ 
lives during treatment.  Lack of onsite counselors, delays in drug test results, and NP 
inexperience were indicated in nurse practitioner responses as a weakness.  The patient consent 
forms were considered extensive with understandability a concern.  Nurse Practitioners disagreed 
about an acceptable patient load.  The NPs who treated a greater number of OUD patients felt 
they could treat a larger number of patients moving forward, while the NPs who treated few or 
no OUD patients suggested a lower patient load.  Such findings may have indicated more 
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experience working with OUD patients could lead to more NP comfort in treating the patient 
population within the confines of the PCC. 
Table J2 
Provider Interview Questions and Responses  
Qualitative Interview Question Provider Responses 
What do you perceive as the strengths of the 
program? 
Access to medical care by accepting patients without health insurance.  
Utilizing the Action Plan sliding scale fee to assist with patient’s ability to 
pay. 
Treatment that allows more normalized routine such as work, family, and 
other responsibilities.  
Patient comfort receiving treatment in an office setting. 
Support from providers, clinic staff and addiction counselors at the CDRC. 
What are the weaknesses of the program? Lack of addiction counselor within the PCC.  
Inexperience with treating OUD patients. 
Lack of rapid, inhouse drug testing and nursing staff to support expanded 
MAT program.  
Only taking referrals from one facility (CDRC). 
What are your opinions about the referral 
process and relationship with CDRC 
employees? 
Knowledgeable and good communication. 
Good working relationship.  
Having a counselor on site may limit miscommunications.  
What have been the biggest barriers for 
providers and the clinic in first three months 
of the program? 
Proper dosing 
Assessing appropriateness for outpatient treatment  
Getting patient set up for outpatient treatment  
Informing the community about MAT service 
Not enough experience due to low patient volume 
Do feel the evaluation process is 
comprehensive and meets the needs of 
providers, the clinic, and the patients? 
Explain your answer. 
CDRC does initial evaluation prior to referral which can lead to some 
miscommunication and discrepancies.  
Both providers and patients seem satisfied with the evaluation and treatment 
process.  
CDRC provides some formal education.  
What is your current patient load and what do 
you believe is an acceptable patient load 
going forward? 
Between 0-5 patients 
Acceptable patient loads vary, but providers managing a greater number of 
OUD patients list a higher number of acceptable patients. Some providers are 
not able to give a definitive number, while others feel between 5 and 20 is 
acceptable. 
What factors have promoted patient retention 
in the program? 
Availability and access to other services 
Supportive environment  
Commitment to recovery and following contract/guidelines.  
Have you found the program forms or 
evaluation tools lack clarity? If so, how? 
Forms are acceptable and do not lack clarity.  
However, forms are long, and patients may not read them carefully or 
understanding them, especially if they are going through withdrawal.  
What recommendations for improvement 
would you like to see made to the program? 
In-house counselor 
Case manager to follow-up with patient compliance  
Better understanding of which patients are outpatient appropriate and which 
need more complex care.  
More general in-house support services.  
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Recommendations for Further Action 
Results generalized within the confines of the PCC may indicate more experience 
working with OUD patients could lead to increased nurse practitioner confidence in treating the 
patient population.  Offering MAT through the primary care setting may increase the availability 
of treatment options for OUD patients while NPs may further address gaps in patient access to 
high quality, patient-centered, and affordable health care.  Future research may focus on patient-
specific outcomes, patient satisfaction, and provider satisfaction of collaborative programs 
compared to independent programs.  Considerations in forming an alliance with more addiction 
treatment organizations may allow NPs more opportunity to treat OUD patients and increase 
patient volume.  Formation of a lobby group comprised of providers and staff from the PCC and 
CDRC may advocate for improving access to MAT for OUD at the city government and state 
government levels.  Finally, the blueprint from this pilot project may also be beneficial to other 
clinics considering starting a MAT for OUD program.  
   
